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ABSTRACT
A Potential Solution to a Poopy Problem: Bile Salt Analogs as Prophylactics
Against Clostridium Difficile Infection (CDI)
by
Jacqueline Renee Phan
Dr. Ernesto Abel-Santos, Examination Committee Chair
Professor of Biochemistry
University of Nevada, Las Vegas
Clostridium difficile infection (CDI) is a major cause of antibioticassociated diarrhea. In 2011, over 500,000 patients were diagnosed with CDI in
the United States and over 29,000 people died of CDI-related complications.
With an average of $35,000 to treat a single case of inpatient CDI, cost burden
to the healthcare system can reach up to $3.2 billion annually. As both hospitaland community-acquired CDI incidences rise due to the emergence of
hypervirulent strains and CDI reoccurrences of up to 25%, standard treatments
are rendered less effective and new methods of prevention are critical.
CDI is caused by bacteria called Clostridium difficile. A key characteristic
of Clostridium difficile is its ability to form tough and dormant structures called
spores. The spores’ dormant nature allows them to survive in the gastrointestinal
tract of susceptible patients without showing any signs of infection. When the
spores are under stress, they can germinate into toxin-producing cells that cause
symptomatic infection.
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Clostridium difficile spore germination is promoted by the bile salt
taurocholate with the amino acid glycine. Another naturally-occurring bile salt
called chenodeoxycholate (CDCA) can compete with taurocholate to inhibit
spore germination. These bile salts are regulated by the indigenous gut
microbiota. However, for patients who are immunocompromised or who have
recently taken antibiotics, the composition of natural intestinal microflora can
become altered, making bile salt regulation much less efficient, thus allowing
spore germination to occur.
Previously, CamSA, a synthetic bile salt analog of taurocholate, was found
to be a more potent germination inhibitor than CDCA when tested against
epidemic type X strain 630. Currently, a new analog called 07C revealed to be
a stronger germination inhibitor than CamSA in strain 630 as well as in various
other strains. Plated germination inhibition assays showed that 07C inhibited
spore germination in several strains of C. difficile using less than 50 μM of
compound. Furthermore, mice challenged with each of the C. difficile strains
had significantly reduced CDI symptoms or were completely protected from
CDI symptoms when given three doses of 50 mg/kg 07C. From these
explorations, bile salt analogs have the potential to serve as CDI prophylactic
treatments in antibiotic-treated patients.
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CHAPTER 1
INTRODUCTION
1.1 Background and Significance
Clostridium difficile is a pathogenic bacterium linked with Clostridium
difficile antibiotic-associated diarrhea. Collectively, disease caused by this
bacterium is recognized as Clostridium difficile infection (CDI). The discovery of
C. difficile was preceded by the characterization of pseudomembranous colitis
(PMC) by John Miller Turpin (J.M.T.) Finney in 1893.1 PMC is an inflammatory
condition in which exudative plaques form on the intestinal mucosa causing
necrotizing disease. As a surgeon at Johns Hopkins Hospital, Finney discovered
PMC in an autopsy of a postoperative patient who had undergone a
gastroenterostomy for an ulcerated pylorus.1,2 Although the patient began to
recover ten days post-surgery, the patient soon developed bloody diarrhea and
succumbed five days later.1 Over the next 50 years, other similar cases were
reported involving postoperative PMC.2-4 By the 1950s, several reports of
diarrhea and colitis were associated with prior exposure to antibiotics.5-8
Meanwhile, in 1935, while investigating the colonization of bacteria in the
gastrointestinal (GI) tracts of human neonates, Ivan C. Hall and Elizabeth
O’Toole isolated bacteria they named “Bacillus difficilis” from the stools of the
healthy newborn infants.9 The name “difficilis” arose from the bacterium’s initial
difficulty to isolate and culture from human feces. While working with “Bacillus
difficilis”, Hall and O’Toole found that the organism was able to produce toxin
1

that was lethal to guinea pigs.9 Interestingly, the infants of which the organism
was discovered from were found to be asymptomatic carriers of the bacterium.9
Thus, the organism was deemed as commensal. A 2011 comprehensive review
by Kachrimanidou and Malisiovas reported that approximately 5% of healthy
adults and 50% of newborn infants are asymptomatic carriers of C. difficile.10
It was not until the 1970s, when the antibiotic clindamycin was first
introduced, that “Bacillus difficilis”, now renamed to Clostridium difficile, was
found to be responsible for antibiotic-associated diarrhea and a primary cause
of PMC.11-14 Moreover, the toxins produced by C. difficile were implicated as the
causative agents of PMC.15-18 By 1996, United States hospital discharges from
Clostridium difficile antibiotic-associated diarrhea were 31 cases per 100,000
population.19,20 This proportion doubled to 61 cases per 100,000 population by
2003.19,20
In 2011, the Centers for Disease Control (CDC) reported that over 500,000
people were diagnosed with CDI in the United States.21,22 In that same year,
approximately 29,000 people died of CDI-related complications within 30 days
of initial diagnosis.22 With an average of $35,000 to treat a single inpatient case,
cost burden to the United States healthcare system can reach up to $3.2 billion
annually.22-26 Some studies have even traced CDI as the cause of $4.8 billion in
excess cost to United States acute-care facilities.27 A 2011 study by Miller et al.
suggests that CDI has even surpassed the infamous methicillin-resistant
Staphylococcus aureus (MRSA) as the most common cause of hospital
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associated infections (HAIs) in community hospitals in the southeastern United
States.28

1.2 Biology of Clostridium difficile
1.2.1 Taxonomy
Clostridium difficile is a member the Domain Bacteria and Kingdom
Eubacteria (Figure 1.1). It belongs to the Phylum Firmicutes. Like most of the
bacteria in Phylum Firmicutes, C. difficile is Gram-positive, which means that it
contains a thick peptidoglycan cell wall that can readily absorb the primary
stain crystal violet.29,30 Once the stain becomes fixed to the cells upon
application of the mordant iodine, the C. difficile rods can be viewed as purple
under light microscopy (Figure 1.2). By contrast, Gram-negative bacteria, such
as Escherichia coli, possess a thin peptidoglycan layer sandwiched between an
inner cytoplasmic cell membrane and an outer membrane composed of
lipopolysaccharides.31,32 This causes Gram-negative organisms to not retain the
primary stain crystal violet after decolorization with alcohol, but readily uptake
the secondary stain safranin. Therefore, they appear pink under light microscopy
(Figure 1.2). This staining technique was devised by Danish bacteriologist Hans
Christian Gram in 1884 as a means of separating bacteria into two distinct
groups based on their cell wall content (Figure 1.3).29,30 Phylum Firmicutes
bacteria are also known for their low percentage of guanine-cytosine (GC)
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nitrogenous base content in their genetic information (DNA or RNA). The C.
difficile genome has been reported to have a 29.06% GC content.33

Figure 1.1. Classification of Clostridium difficile.

E. coli

C. difficile

Figure 1.2. Gram stain of Gram-positive C. difficile (purple) and Gram-negative E. coli (pink).
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Figure 1.3. Representation of Gram-staining technique. Heat-fixed bacteria are stained with
the primary stain crystal violet for 1 minute, then washed with water (Step 1). The mordant
Gram’s iodine is then added for 1 minute to fix the crystal violet dye to Gram-positive
bacteria (Step 2). After washing with water, alcohol is added for 10-20 seconds to decolorize
Gram-negative bacteria. Finally, the secondary stain safranin is added for 1 minute to
counterstain Gram-negative bacteria (Step 4). Excess stain is washed with water. Grampositive bacteria will appear purple while Gram-negative bacteria will appear pink under
light microscopy.

Phylum Firmicutes consists of two major classes of rod-shaped bacteria:
Bacilli and Clostridia (Figure 1.1). While Bacilli can be obligate or facultative
aerobes, Clostridia are obligate anaerobes.34,35 This means that they do not
tolerate the presence of oxygen, and thus use nitrate as their final electron
acceptor in cellular respiration to produce molecular energy in the form of the
adenosine triphosphate (ATP).34-36 Therefore, the anaerobic nature of the
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mammalian GI tract coupled with its high nutrient availability allows C. difficile
the ability to thrive within it.37
C. difficile is further classified into Order Clostridiales and Family
Clostridiaceae (Figure 1.1). As with other bacteria in Family Clostridiaceae, C.
difficile is able to form structures called endospores.30,35 Endospores are very
often referred to as “spores” although they are not true spores in the sense that
they are not reproductive offspring (such as with plants or fungi), but rather are
non-reproductive seed-like entities. Endospores are tough and dormant
structures that are formed when the vegetative cell is exposed to harsh or
stressful conditions like nutrient deprivation. These spores are highly resistant to
various stressors such as high temperatures, ultraviolet irradiation, and a variety
of antimicrobial treatments.38-40 Their dormant nature also allows them to survive
on surfaces such as hospital counters and in the GI tracts of susceptible
patients.41
Finally, the genus Clostridium contains about 200 species that consist of
non-symbiotic bacteria, commensal bacteria, as well as notorious pathogenic
bacteria such as C. botulinum (responsible for botulism), C. perfringens
(responsible for gas gangrene), C. tetani (responsible to tetanus), and C. difficile
(responsible for CDI) (Figure 1.1).34
C. difficile strains are highly motile and move via peritrichous flagella,
which are flagellar extensions that are spread throughout the surface of the
bacterium.42 However, Baban et al. has shown that C. difficile strain R20291
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exhibits monotrichous flagella (a single flagellum on one end of the
bacterium).42 The study suggests that monotrichous flagella assists the strain
R20291 bacteria not only in motility, but also in adherence and colonization to
the intestinal epithelium upon infection.42

1.2.2 Sporulation
The production of endospores is a key characteristic of C. difficile. The
process by which endospores are formed is called sporulation. Sporulation is
triggered by stimuli from both the external and internal environment. External
cues include quorum sensing, nutrient starvation, and desiccation. Following
external stimulus, initiation proteins that comprise of sensory histidine kinases
phosphorylate regulatory proteins including the master transcriptional regulator
protein Spo0A, which is highly conserved among members of the Bacillus and
Clostridium genera.43 Spo0A has been found to be an important factor in the
transmissivity of CDI and play a significant role in maintenance of persistent
infection.43 The recruitment of initiation and regulatory proteins commence a
cascade of sigma (σ) factors and additional sporulation proteins that signal the
formation of the many layers of the C. difficile endospore.44,45
The overall structure of the C. difficile spore is similar that of other sporeforming bacteria in genera Bacillus and Clostridium (Figure 1.4). However, C.
difficile lacks some sporulation orthologs that are commonly conserved in other
species of those genera. This is particularly apparent in the outer layers of the C.
7

difficile spore. The outermost layer of the spore is the exosporium, which contains
hair-like proteinaceous projections that help attach the spore to host cells.45 The
exosporium is also the outermost layer in B. anthracis and B. cereus.45,46
Interestingly, C. difficile spores that possessed defective or missing exosporium
layers were found to adhere better to Caco-2 colonic cells and germinate more
readily than spores with intact exosporiums.45,47

Core
Exosporium
Cortex
Coat

Germ cell wall

Outer membrane

Inner membrane

Figure 1.4. C. difficile endospore structure. Adapted from Paredes-Sabja et al. 2014.45

The exosporium surrounds the next layer, the spore coat, which is
commonly the outermost layer of spores in many other spore-forming bacteria.
Despite many structural similarities, C. difficile only shares less than 25% of similar
spore coat proteins homologs with the well-studied B. subtilis.46 The C. difficile
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spore coat is proposed to contain a dense and rigid polypeptide lattice
consisting of many cysteine residues that form disulfide bridges under aerobic
conditions.46 The spore coat is resistant to harsh chemicals and functions as a
protective barrier to the underlying spore cortex, which is susceptible to
lysozyme degradation.45,46,48 It is also a passageway for small molecules known
as germinants to pass through into the inner spore layers.49
The cortex is sandwiched between an outer and inner membrane. The
cortex is comprised of cross-linked layers of peptidoglycan.50 The cortex plays an
essential role in dehydrating the spore’s core, which contributes to the spore’s
heat resistance. During germination, the process by which the outgrowth of a
vegetative cell occurs, the cortex is degraded by hydrolytic enzymes from the
core. The degradation of the cortex is necessary for the full rehydration of the
core upon germination. Directly underneath the cortex is the germ cell wall
which will become the cell wall of the bacterial cell following germination.
The spore’s inner membrane is a stiff lipid bilayer. For Bacillus and
Clostridium species other than C. difficile, the inner membrane contains the
germination receptors (Ger).48 C. difficile lacks a known Ger receptor, but it is
proposed that its germination receptor is present at this layer.45,51,52 The low
permeability of the rigid inner membrane also aids in the protection of DNA in
the underlying core.45,53,54,55
The innermost spore layer is the core which stores large amounts
dipicolinic acid (DPA) chelated with calcium ions (Ca2+). DPA is suggested to be
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responsibility for the spore’s heat resistance.56 The Ca2+-DPA complex makes up
20-25% of the core’s dry weight.45,57 Also in the core are small acid-soluble
proteins (SASPs) that are tightly bound to DNA. They have been linked with the
spore’s chemical and UV resistance.58 SASPs make up approximately 10-20% of
the core’s dry weight.48,58 Moreover, the spore’s low water content (25-60% wet
weight) also contributes to its resistance capabilities.45,57 In addition to housing
the genetical material of the spore (DNA and RNA), the core also contains
enzymes that are required for degradation of the outer spore layers during
germination and outgrowth.
Endospore formation occurs in a cycle and is characterized by several
key morphological steps (Figure 1.5). In B. subtilis, it can take approximately 3
hours for the first morphological change to occur after sporulation is
inaugurated.44 However, C. difficile can take between 8 to 20 hours for the
same sporulation stage to jumpstart.44 This variability may explain possible
differences in sporulation rates among various C. difficile strains. First, the
vegetative bacterial cell senses an environmental stressor (Stage I). As a way to
preserve the cell’s genetic material, it begins to form the endospore. This first
step is characterized by the formation of a septum on one side of the cell (Stage
II). Following septum formation, the peptidoglycan in the septum begins to
degrade and smaller side of the cell becomes engulfed to form a forespore
(sometimes referred to as the prespore) (Stage III). The remainder of the cell is
referred to as the mother cell. The mother cell produces several endospore10

specific components that aid in the maturation of the fully formed endospore.
The mother cell synthesizes the core and cortex (Stage IV), then manufactures
the germ cell wall, inner membrane, and outer membrane (Stage V). After the
inner layers are formed, the spore coat and exosporium are deposited around
the spore (Stage VI). Once all layers are constructed, the mother cell programs
cell death and lyses, causing the mature endospore to be released and freed
(Stage VII). Upon exposure to ideal conditions and activation by a germinant
(discussed further in section 1.4), the endospore can germinate, resulting in
outgrowth of a vegetative toxin-producing cell (Stage VIII). As a defense
mechanism to protect its DNA, the bacterial cell can reenter the sporulation
cycle to produce more endospores under stressful conditions.
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Figure 1.5. C. difficile endospore life cycle. The vegetative cell senses an environmental
stressor which triggers sporulation (Stage I). A septum is formed (Stage II) and the cell is
asymmetrically split to form a smaller forespore and a larger mother cell (Stage III). The
mother cell assembles the spore core and cortex (Stage IV). Then, the mother cell forms the
germ cell wall, inner membrane, and outer membrane (Stage V). The final manufacturing
step is the deposition of the spore coat and exosporium (Stage VI). The mother cell lyses and
releases the free mature endospore (Stage VII). During spore germination, outgrowth of a
vegetative cell will occur (Stage VIII). The vegetative cell can then reenter into sporulation
under unfavorable conditions. Adapted from Paredes-Sabja et al. 2014.45

The presence of spores can be confirmed by microscopic visualization.
One approach is the Schaeffer-Fulton endospore staining technique which uses
the malachite green to stain spores and safranin to counterstain bacterial cells
(detailed in section 2.2.4.1).59 It was designed in 1933 by Alice B. Schaeffer and
MacDonald Fulton, both of whom were microbiologist at Middlebury College in
Middlebury, Vermont. It is sometimes referred to as the Wirtz-Conklin method
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after the two bacteriologists who originally developed the technique in 1908.59
Schaeffer and Fulton slightly modified Wirtz and Conklin’s previous method by
replacing osmic acid with heat as a fixating agent to provide a technique that
was faster and more efficient than other methods used at that time. One of
those methods was Dorner’s endospore staining technique, published in 1922,
which used Ziehl-Neelsen Carbol Fuchsin (ZNCF) to penetrate into the spores,
causing them to appear red, and 10% Nigrosine to stain the background of the
slide black.59

1.2.3 Toxin Production
Upon germination and outgrowth of C. difficile spores, toxins are
produced and released. These toxins are responsible for the pathogenicity of
CDI and are the determinants for disease. The two major C. difficile toxins are
enterotoxin TcdA (Clostridium difficile toxin A) and cytotoxin TcdB (Clostridium
difficile toxin B), both of which have been implicated in CDI symptoms such as
diarrhea and PMC.21,60,61 Several strains of C. difficile are also capable of
producing a third toxin known as CDT (Clostridium difficile transferase), which
has been frequently implicated in severe cases of CDI.62 Non-toxigenic strains of
C. difficile also exist naturally and do not cause disease.63
TcdA and TcdB are among the largest bacterial toxins known with
molecular masses of 308 kDa and 270 kDa, respectively.60,64 TcdA and TcdB are
encoded by genes tcdA and tcdB, which are found in open reading frames
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situated within the 19.6 kb pathogenicity locus (PaLoc) of the C. difficile
chromosome.65,66 Additionally, tcdA and tcdB genes have low GC content as
does the entire C. difficile genome.60 The toxins also have a high degree of
similarity with 66% homology overall.60
During the early exponential phase of C. difficile cell growth, toxin release
levels are relatively low. At this point, TcdC, a negative regulator of toxin
production, is expressed at high levels.60,67,68 The tcdC gene, which encodes
TcdC, lies downstream of tcdA and tcdB and is transcribed in the opposite
direction.60,67,68 By the late exponential phase to stationary phase, TcdC levels
decline and toxin production significantly increases.60,67,68 Another regulator,
TcdD, encoded by the upstream tcdD gene, has been suggested to be a
positive regulator of toxin production.60,69
TcdA and TcdB are both glucosyltransferases that inactivate intracellular
GTPases (Rho, Rac, and Cdc42 proteins) within target cells.60,70 These GTPases
are regulatory proteins of the actin cytoskeleton.60,71 Both tcdA and tcdB genes
contain four key domains (from C-terminus to N-terminus): the combined
repetitive oligopeptide repeat (CROP) domain, the putative translocation
domain, the cysteine protease domain (CPD), and the glucosyltransferase
domain (GTD). The CROP domain, or receptor-binding domain, binds to
carbohydrate and protein receptors on the surface of the host epithelial cells.
TcdA binds to glycoprotein 96 (gp96) and sucrase-isomaltase on the apical
membrane of human colonocytes; whereas, TcdB binds to chondroitin sulfate
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proteoglycan 4 (CSPG4) and poliovirus receptor-like 3 (PVRL3) on the surface of
intestinal epithelium.60,70-73 Upon interaction with the host cell receptors, the
toxins are internalized via endocytosis. The endosome acidifies, causing the
toxins to partake in conformational changes that allow for their translocation
into the cytoplasm. Once the toxins are internalized into the host cell, toxins are
auto-catalytically cleaved by their CPD domain, thus activating GTD, the
catalytic domain. GTD aids in the transfer of glucose from UDP-glucose to the
target GTPases, rendering them inactive. The glycosylation of the GTPases
triggers modification of the actin cytoskeleton and increased permeability of
tight junctions, leading to epithelial cell damage, increased fluid secretion,
mucosal necrosis, and apoptotic cell death.21,60 Increased epithelial
permeability also leads to neutrophil infiltration and accumulation, which are
the hallmarks of pseudomembranous colitis (PMC) (Figure 1.6).21,60,70

15

Pseudomembrane

Figure 1.6. Simplified representation of toxin release contributing to pseudomembranous
colitis (PMC). Adapted from Voth & Ballard 2005, Rupnik et al. 2009, and Abt et al. 2016.21,59,69

The detection of TcdA and TcdB have long been paramount for
diagnosing CDI. Immunoassays and cytotoxicity assays have been employed to
detection the presence of toxins. Enzyme immunoassay (EIA) tests have quick
turnover times and can detect the presence of free TcdA and TcdB in stool.74-76
Due to their low sensitivity, toxin EIAs are usually not used as stand-alone
diagnostic tools.77,78 The cell cytotoxicity neutralization assay (CCNA) have been
long considered as the “gold standard” for C. difficile toxin detection.77-79
CCNAs take the filtrate of collected stool samples and test them against
mammalian cell cultures; cell round up and necrosis are indicative of the
presence of TcdB. Verification of C. difficile toxin as the cause of cytopathic
effects is determined by neutralization with specific antitoxin antibodies.78,79
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While highly sensitive and specific, the CCNA has a slow turnaround time and
requires technical expertise.79 The nucleic acid amplification test (NAAT) uses
real-time quantitative polymerase chain reaction (RT-PCR) to amplify C. difficile
toxin gene fragments.80 However, this method does not account for the
expression of active toxins.
CDT is a ribosyltransferase that was first discovered in C. difficile strain
CD196 by Popoff et al. in 1988.62,81 It was found to exhibit ADP-ribosyltransferase
function similar to Clostridium botulinum toxin C2 and Clostridium perfringens
toxin E iota. As a binary toxin, it is composed of two separate proteins: CdtA, the
enzymatic component, and CdtB, the binding component. CDT binds to the
lipolysis-stimulated lipoprotein receptor (LSR) on the surface of intestinal
epithelial cells. Similar to TcdA and TcdB, CDT is internalized via endocytosis.
CdtB creates a small pore in the acidified endosome facilitating the release of
CdtA into the cytosol. There, CdtA ribosylates G actin, collapsing the host cell’s
actin cytoskeleton by inhibiting actin polymerization and promoting fibronectin
microtubule elongation and protrusion. Furthermore, this fosters C. difficile’s
adherence to the intestinal epithelium.62,82
CDT has been associated with hypervirulent (severe disease-causing) C.
difficile strains such as the epidemic strain BI/NAP1/027.62,83 In addition to TcdA
and TcdB, BI/NAP1/027 strains are also capable of producing active CDT.
Although many other factors account for the virulence of BI/NAP1/027 strains, it
is possible that CDT has synergistic effects with TcdA and TcdB. More on
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hypervirulence and BI/NAP1/027 strains will be discussed in section 1.3.5 and
chapter 2.

1.3 Clostridium difficile Infection (CDI)
1.3.1 Disease Characteristics
Clostridium difficile Infection (CDI) is a primarily nosocomial disease
caused by Clostridium difficile. It is predominately linked to patients who have
had prior antibiotic use.84,85 Individuals who are elderly or immunocompromised
are also disproportionately affected and are more susceptible to disease.21 Use
of antibiotics such as clindamycin can disrupt the natural colonic gut flora, thus
removing the beneficial bacteria and allowing for the colonization of C. difficile.
Due to the resistant nature of C. difficile spores, they can survive passage
through the acidic stomach, the small intestine, and into the large intestine
(colon).38 When in the intestines, the anaerobicity and nutrient-rich environment
promotes the spores to germinate into toxin-producing vegetative cells that are
capable of eliciting disease.
CDI symptoms can range from mild to severe disease. Mild disease is
defined solely as the presence of diarrhea.85,86 Moderate disease includes a
repertoire of other symptoms such as abdominal pain, loss of appetite, fever,
nausea, vomiting, GI bleeding, bloody stools, and weight loss.85 Severe disease
includes the same symptoms associated with mild-to-moderate diarrhea with
the addition of more serious conditions such as elevated white blood cell
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counts, hypotension, high grade fever, pseudomembranous colitis (PMC), ileus
(the reduction in peristaltic movement of stools through the GI tract), abdominal
distention, altered mental status, and organ failure.85 PMC can lead to another
grave condition called toxic megacolon, which renders the colon incapable of
expelling gas and stool, potentially leading to rupture. Moreover, organ failure
can ultimately lead to death.

1.3.2 Mode of Transmission
CDI is transmitted through an oral-fecal route (Figure 1.7). C. difficile
spores can be ingested through the oral cavity and shed through feces. In
healthy individuals, indigenous gut bacteria will assist in the regulation of bile
acids that aid in the prevention of spore germination.87-89 Thus, the spores that
enter the body will exit the body as spores.90 However, in patients with depleted
gut microflora, C. difficile spores can germinate in the colon and cause CDI
symptoms.73,87-89
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Figure 1.7. Route of transmission of C. difficile spores through mammalian host. C. difficile
spores (green circles) are ingested by the mammalian host. The spores’ dormant and
resistant nature allows them to survive the stomach’s low pH until they eventually reach the
lower GI tract. In the large intestine, the spores germinate into toxin-producing cells (purple
rods). To aid in their survival, these vegetative cells also produce spores that can exit the
body through feces. The excreted spores can re-infect the original host or infect another host
through ingestion.

The spore’s resistant qualities may allow it to survive for long periods of
time. Contaminated surfaces, instruments, and equipment such as counters,
beds, and gloves can become reservoirs for C. difficile spores. Therefore,
decontamination is critical in the prevention of CDI from spreading. Proper hand
hygiene and glove wearing are initial preventative measures used in hospitalrelated settings as precautions when working with CDI patients. Some hospitals
have also implemented infection control programs.85,91 Because C. difficile
spores are resistant to alcohol-based cleaners, disinfectants that contain a
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minimum of 5,000 ppm of chlorine are recommended to kill the spores. Isolation
of patients may also be required to reduce transmission from person to person. A
cohort studied showed that patients in double rooms are more likely to acquire
CDI than patients placed in single rooms.85,92
Traditionally, CDI has been considered a nosocomial disease. However,
some studies have also isolated C. difficile outside of the hospital setting in nonhuman reservoirs. C. difficile has been found in food as well as domestic
animals.93-95 This could be one possible mode of transmission in the communityacquired CDI setting.
For some individuals, C. difficile is indigenous rather than acquired through
transmission.10,96,97 These individuals are often asymptomatic C. difficile carriers
and have the presence of other intestinal microbes that keep C. difficile in
check to manageable quantities. Asymptomatic carriers have also been shown
to be less susceptible to CDI even under antibiotic therapy. This may possibly be
attributed to their natural immune system. A study by Sanchez-Hurtado et al.
suggested that carriers have increased antibody response to C. difficile.98
Another study done by Kyne, Warny, Qamar, and Kelly showed that higher
production of the antibody immunoglobulin G (IgG) against Clostridium difficile
toxin A helps confer immunity.99 Nevertheless, asymptomatic carriers may still
pose a risk for transmitting C. difficile to vulnerable individuals.97
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1.3.3 Establishment of Infection
There are three steps at the host level that enable the establishment of
CDI: ingestion of spores, susceptibility to CDI due to antibiotic exposure, and loss
of a natural protective barrier in the GI tract. Infection begins with the ingestion
of C. difficile spores from the environment. In most archetypal CDI models, the
host must become predisposed to CDI by antibiotic usage. Prior to antibiotic
treatment, the gut flora is naturally in symbiosis (Figure 1.8). Antibiotics disrupt the
natural microbiota within the GI tract causing dysbiosis (Figure 1.8). The loss of
the natural protective barrier in the gut allows for C. difficile overgrowth and
accumulation (Figure 1.8). Moreover, the depletion of beneficial gut microbes
results in a crucial loss in the regulation of various factors involved in inhibiting
the establishment of infection such as germination inhibition.
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Figure 1.8. Changes in gut microbiota due to antibiotic use. During symbiosis, the natural
intestinal microflora is present. During exposure to antibiotics, the microbiota is disrupted,
destroy some beneficial microorganisms and causing dysbiosis. Once C. difficile is introduced
into the host, the dysbiotic environment allows C. difficile to allocate space and nutrients
resulting in overgrowth and accumulation.

At the spore level, there are also three steps to establishing infection: the
entrance of the spore into the host, germination of the spore, and production of
toxins. Spores are the vehicle for infection. Although they do not cause disease
symptoms, they are the infecting agents that enter the host and set the
foundation for infection. Once the spores pass the acidic stomach, the
favorable environment in the small intestine along with the presence of key
germinants, in the form of bile salts and amino acids, promote spore
germination.49,52,87,89,100 While the spore prepares for the outgrowth of vegetative
cell, the spore travels to the large intestine (colon). There, the resultant
metabolically active vegetative cells produce toxins, which are the
determinants for disease. The internalization of the toxins eventually recruits
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neutrophils that cause an inflammatory response, giving rise to diarrheal
symptoms and pseudomembranous colitis. Sporulation by the vegetative cells is
also localized to the colon.

1.3.4 Current Treatment Options
CDI is usually instigated by broad-spectrum antibiotics used to treat other
illnesses. Patients who are on cephalosporins, fluoroquinolones, and clindamycin
are at even higher risk for contracting CDI.101 Once CDI is diagnosed, timely
treatment is crucial. Ironically, CDI patients usually must stop taking those
antibiotics to begin taking CDI-specific antibiotics. Conventionally, the
antibiotics metronidazole and vancomycin have been used to treat CDI.
Metronidazole (trade name Flagyl) is a nitroimidazole antibiotic that is
active against anaerobic bacteria (Figure 1.9). Due to its small size and low
molecular weight, it can passively diffuse through the C. difficile cytoplasm.
Metronidazole acts by stealing electrons from bacterial electron transfer proteins
flavodoxin and ferredoxin. This results in a nitroso free radical that hinders nucleic
acid synthesis. Metronidazole is used to treat mild-to-moderate CDI. However,
metronidazole is usually avoided in prolonged treatment as long-term use has
been linked with neurotoxicity and hepatotoxicity.86,102 Also, resistance to
metronidazole has previously been reported and can arise from factors such as
slow drug activation, increased drug efflux, and horizontal gene transfer of
nitroimidazole resistant genes.86,103
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For more moderate-to-severe cases of CDI, vancomycin is usually the
drug of choice. Vancomycin (trade name Vancocin) is a cell wall inhibitor that
targets mainly Gram-positive bacteria by preventing the synthesis of
peptidoglycan (Figure 1.9).104-107 It forms hydrogen bonds with the terminal Dalanyl-D-alanine residues of N-acetylglucosamine (NAG) and N-acetylmuramic
acid (NAM) peptides of the peptidoglycan layer. Vancomycin also prevents
spore outgrowth.108 As a large hydrophilic molecule, vancomycin is poorly
absorbed from the intestines. Therefore, in order to reach the site of infection
(the GI tract), vancomycin must be administered orally for CDI cases.104,107,109,110
Unlike metronidazole, C. difficile has not yet been reported to show resistance to
vancomycin.106 However, vancomycin is much more expensive than
metronidazole.
Vancomycin can be used in conjunction with metronidazole to treat CDI
recurrences, thought it may not be successful in preventing them. Because
metronidazole and vancomycin both target a broad range of bacteria, they
can suppress the growth of the intestinal microbiota, resulting in a high
frequency of relapse.107,111,112 In recent years, a newer antibiotic called
fidaxomicin (trade name Dificid) has been used in metronidazole- and
vancomycin- failed treatment (Figure 1.9).106,107,111-113 Fidaxomicin was originally
isolated from Dactylosporangium aurantiacum subspecies hamdenesis and is a
macrocyclic antibiotic.113 Fidaxomicin prevents the opening and closing of the
DNA/RNA clamp responsible for the initiation of transcription. Although
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fidaxomicin shows minimal disruption to the indigenous gut microflora, one
caveat is that it is relatively ineffective against recurrent CDI.111,114 Despite this,
fidaxomicin has been associated with lower rates of recurrence.111

Figure 1.9. Chemical structure of clinically relevant antibiotics used to treat CDI.

Several novel treatment options are available for patients suffering from
CDI. For more extreme cases of CDI, fecal microbiota transplantation (FMT) is an
alternative approach to treating multiply-recurrent CDI. FMT is the introduction
of healthy donor stools into the colon of CDI patients (Figure 1.10). This method is
used to restore the diverse gut microbiota that was killed off by antibiotics and
reinstate resistance to C. difficile colonization. FMT is typically administered via
colonoscopy, endoscopy, or through an enema, but can also be taken as a
frozen oral pill.115,116 Although success rates are generally high (86-99%), the
procedure can be aesthetically unappealing.115,117 The perceived concern for
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transmission of infectious agents of the donor stools has also been a topic of
concern.85,115 However, a 2011 review found that there were no reported
infection transmission reports in over 370 published studies.118 Regardless, donor
stools undergo careful selection and rigorous screening prior to being used in
treatment, which increases the cost of the treatment.119

Figure 1.10. Representation of fecal microbiota transplantation (FMT). Donor stools are
carefully screened and selected for use in FMT (Step 1). The stools are blended, strained, then
stored in a freezer (Step 2). Prior to treatment, the stools are portioned (Step 3) and
administered to the patient via colonoscopy/endoscopy tube, enema, nasogastric tube,
nasoduodenal tube, orogastric tube, or oral capsule (Step 4).

Other novel treatments include the use of probiotics, vaccines, and
antitoxins. Like FMT, probiotics introduces “good” microorganisms into the GI
tract of CDI patients (Figure 1.11). Unlike FMT, it usually only includes a few
specific combinations of microbial species. Common microorganisms included
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in probiotics are Saccharomyces boulardii, Lactobacilli, Clostridia, Streptococci,
and Bifidobacteria. Lactobacilli and Bifidobacteria are ordinarily found in yogurt
and dairy products, respectively. Probiotics are usually administered in tablet
form. Several meta-analyses have shown probiotics to be useful in treating
Irritable Bowel Syndrome (IBS) and CDI.120,121 A few sporadic cases of probiotic
therapy have reported bloodstream infections due to bacteremia and
fungemia in immunocompromised patients.122,123 This brings up the concern of
probiotic safety evaluation as they are currently not overseen by a major
regulatory entity.124,125 Probiotic therapy, along with other innovative treatment
options such as vaccines and antitoxins, are still relatively new and theirs benefits
with treating CDI are still under investigation.126-129
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Figure 1.11. Representation of probiotic therapy. First, the patient ingests the probiotic
supplements in the form of a pill or tablet (Step 1). Microorganisms in the probiotics are
introduced into the intestinal environment and act to restore microbial balance by either
bringing beneficial bacteria to the GI tract (during depletion of the gut microbiota) or by
competing with C. difficile for resources and thus reducing colonization (during C. difficile
overgrowth) (Step 2).

1.3.5 The CDI Dilemma
Previously, CDI has been associated with those who are in a hospitalrelated setting or those who are elderly and/or immunocompromised. However,
in the past decade, CDI has been on the rise in both hospital and community
settings. CDI incidences rose due, in part, to emergence of hypervirulent
strains.102,130-133 Hypervirulent strains, such as the previously introduced
BI/NAP1/027 strains, exhibit a wide variety of characteristics that attribute to their
“hypervirulence”.83 Hypervirulent strains can exhibit increased sporulation rates,
increased toxin production, or sometimes both, which can contribute to more
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severe diarrhea and disease progression, increased recurrence, and higher
mortality rates.132
The emergence of new strains has also been noted as the probable
cause of the growing problem of community-acquired CDI. As briefly discussed
in section 1.3.2, food and domestic animals can be a possible source of CDI
transmission in the community setting. In addition, transmission through
asymptomatic carriers and healthcare workers have also been reported.
However, many community-acquired CDI cases have shown an absence of
classic risk factors for CDI such as antibiotic exposure, elderly age,
comorbidity/immunosuppression (e.g., cancer, HIV), and a clinical setting.93 The
multitude of discovered C. difficile strains make it increasingly difficult to treat
CDI with standard methods.132-136 Some strains are also specific to certain
settings and geographical regions.83,131,136-138 PCR-ribotyping, which is a method
of bacterial identification based on the similarities of polymorphisms in the 16S
rRNA gene, allows researchers to categorize these different C. difficile strains into
groups, making similarities and differences between strains easier to
identify.135,139-141
Treatment of CDI and other afflictions with broad-spectrum antibiotics
can also produce a viscous cycle of antibiotic use, which further predispose
individuals to CDI recurrences. With CDI recurrences of up to 25%, standard
treatments are rendered less effective.111,112 As a multi-faceted problem, new
avenues of treatment for CDI need to be explored. The dilemma with CDI is that
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it is an antibiotic-associated disease that is commonly treated with antibiotics.
Therefore, finding prophylactic/preventative methods are critical.

1.4 Spore Germination and Inhibition
1.4.1 Germination
Spore germination is necessary for the establishment of CDI. When the C.
difficile spore is exposed to ideal conditions, such as the anaerobic, nutrient-rich
GI tract, germination can occur. This phenomenon begins with the hydration of
the spore. As water enters the spore, large amounts of Ca2+-DPA complex are
released from the spore. Hydrolytic enzymes are also released from the spore
core to degrade the cortex and spore coat. The destruction of the cortex is
necessary for the full hydration of the anhydrous core.45,48,142,143 SASPs are
hydrolyzed into smaller amino acids that are used for the outgrowth of the
vegetative cell. The germ cell wall also becomes the cell wall of the bacterial
cell.
Spore germination is expedited by the presence of germination promotors
called germinants. When the germinants bind to the spore, the germination
process is irreversible.48,88 In most Bacillus and Clostridium species, spore
germinants include amino acids, saccharides, nucleosides, and ions.45,49 In
contrast, C. difficile spore germinants are specific bile acids that are initially
produced by the liver or are later modified in the intestines.87 These germinants
are proposed to bind to Ger receptors on the spore.54,144 C. perfringens possess
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three germination-specific subtilisin-like serine proteases, CspA, CspB, and CspC,
that act by cleaving lytic enzymes responsible for degrading the spore
cortex.145-147 In C. difficile, CspA and CspC are predicted to be catalytically
dead. However, a 2013 study by Francis et al. suggested that mutations in CspC
alter the spore’s response to bile salts.147 Identification of a putative C. difficile
germination receptor is currently being studied.

1.4.2 The Role of Bile Salts on Spore Germination and Inhibition
Past studies have showed that bile acids play an instrumental role in the
promotion and inhibition of C. difficile spore germination.87-89,100 Bile acids are
steroid compounds that are produced in the liver and stored in the gallbladder.
Upon released from the gallbladder, their primary function is the emulsify
(physically separate) larger fat aggregates to aid in lipid digestion and
reabsorption in the small intestines.
The synthesis of bile acids begins in the liver with cholesterol (Figure 1.12).
In the liver, cholesterol is converted to the primary bile acids
chenodeoxycholate and cholate through several enzymatic steps.89,148,149 With
the addition of the amino acid glycine or the amino acid derivative of cysteine
called taurine, the primary bile acids become conjugated bile acid (also known
as bile salts). For chenodeoxycholate, the bile salt derivatives are
glycochenodeoxycholate and taurochenodeoxycholate. For cholate, the bile
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salts counterparts are taurocholate and glycocholate. The liver secretes the
synthesized bile acids as bile salts.
Once the gallbladder releases bile containing bile salts into the intestines,
the gut microbiota takes over the modification of the bile salts (Figure 1.12). In
the upper ileum, bile salt hydrolases, produced by many intestinal microbes,
deconjugate the bile salts by cleaving their amino acid side chains and
converting them back into primary bile acids.89,149 When unabsorbed bile acids
reach the lower ileum, indigenous clostridial species such as C. scindens
dehydroxylates the primary bile acids via 7α-dehydroxylase.89,150 The products
are lithocholate (from chenodeoxycholate) and deoxycholate (from cholate).
These are known as secondary bile acids. Most of the bile acids are reabsorbed
through active transport by ileal mucosal cells and transported back into portal
blood by enterohepatic circulation.151,152 Interestingly, while chenodeoxycholate
is very readily absorbed into the gut, its dehydroxylated derivative lithocholate is
poorly absorbed. Accumulation of lithocholate in the colon revealed
carcinogenic properties in the early stages of colon cancer.153
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Figure 1.12. Synthesis of bile acids in the liver and GI tract. Adapted from Shen 2015.89

Bile acids also have a secondary role of regulating C. difficile spore
germination, though they are at the mercy of the indigenous gut microflora that
are responsible for maintaining them through conjugation and hydrolysis.
Taurocholate, and to lesser extents, cholate and glycocholate, have been
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found to be natural germinants of C. difficile spores; whereas,
chenodeoxycholate was discovered to be a natural germination inhibitor
(Figure 1.12).88,154,155 Taurocholate also requires a co-germinant, the amino acid
glycine, to activate C. difficile spore germination.52,87 Although glycine alone
does not promote germination, it acts synergistically with taurocholate by
increasing cooperative binding affinity to the spore.52 In a state of symbiosis such
as in a healthy digestive tract, native bacteria keep the amounts of bile acids
present in the gut in check.89,156 Hence, there are less germinants and more
inhibitors present as bile acids move further down the GI tract (Figure 1.13). Due
to the careful balance of bile acid content, the C. difficile spores that enter the
gut do not germinate and are shed in feces.90 However, in patients who have
depleted gut microbiota induced by antibiotics, a state of dysbiosis is present.
Therefore, the remaining microorganisms are much less efficient at regulating
the bile salts. Consequently, there is a buildup of germinants and lower presence
inhibitors are present further down the gut (Figure 1.13). C. difficile spores
entering the body are more likely to germinate around the increased
attendance of germinants, causing CDI symptoms.
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Figure 1.13. Simplified representation of change in gut bile acid pool during symbiosis versus
dysbiosis. During symbiosis, intestinal bacteria maintain healthy levels of bile acids. Therefore,
there is less taurocholate and more chenodeoxycholate as bile acids are moved down the
GI tract. Resultantly, spores do not germinate and are shed in feces. The opposite is true
during dysbiosis, thus manifesting in the germination of spores and initiation of CDI.

1.4.3 Targeting the Germination Pathway
Due to spore germination being a pivotal step in CDI establishment, antigermination therapy has been proposed as a CDI prophylactic target. Past
studies in the Abel-Santos Laboratory have proposed the production of synthetic
bile salt analogs to compensate for the imbalance in key natural bile salts due
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to antibiotic-associated microflora disruption. It was hypothesized that modifying
the side chain of cholate (cholic acid) would result in possible competitive
inhibitors of cholate derivatives for the binding to the C. difficile spore (Figure
1.14).

Figure 1.14. Synthetic bile salt analogs are cholic acid derivatives with modified side chains.

One successful synthetic bile salt analog called CamSA is a cholate with a
meta-aminobenzene sulfonic acid side chain (Figure 1.15). Through kinetic
analysis, CamSA was shown to be a 275 times better binder to the spore than
taurocholate and was found to be a five times better germination inhibitor than
chenodeoxycholate. CamSA was found to be a germination inhibitor in strain
630 and VPI 10463 in vitro.157 CamSA had half maximal inhibitory concentration
(IC50) of 58.3 μM against strain 630 spores.100 In mice challenged with C. difficile
strain 630, CamSA was able to prevent CDI with a single 50 mg/kg dose.157
Furthermore, CamSA showed no observable toxicity to mice.90,157 In studies with
simulated gastric and intestinal juices, CamSA remains stable.90 Despite being
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highly susceptible to CDI, hamsters given C. difficile strain 630 with CamSA
showed reduced CDI symptoms when coupled with vancomycin therapy.
Following these initial CamSA studies, the effects of CamSA against other
strains of C. difficile needed to be uncovered. After preliminary testing of
CamSA with the hypervirulent BI/NAP1/027 strain R20291, CamSA was unable to
prevent spore germination in vitro. Although CamSA was infective against strain
R20291 in vitro, it’s in vivo effects were still of interest. It is also possible that
CamSA is potent against other strains of C. difficile that were not yet tested. To
find a new potent germination inhibitor, over 200 CamSA analogs were
screened. Of the compounds tested, one compound called 07C was
discovered to inhibit spore germination in both germination in strain 630 as well
as strain R20291 both with less than 10 μM concentrations (Figure 1.15). Other
screened compounds did not display as promising preliminary results as 07C,
though many more compounds are still being screened in the Abel-Santos
Laboratory.
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Figure 1.15. Chemical structure of the two bile salt analogs used in this study. CamSA is a
meta-aminobenzene sulfonic acid derivative of cholate. 07C is an aniline derivative of
cholate.

1.5 Specific Aims of This Study
The first specific aim of this study is to test synthetic bile salt analog
compounds against various C. difficile strains in vitro. Prior to this study, CamSA
analogs were pre-screened in vitro via germination assays that helped identify
each compound’s potential to inhibit spore germination. The compound that
possessed the lowest inhibitory concentration against the hypervirulent C.
difficile strain R20291 was the cholic acid aniline derivative 07C. Therefore,
CamSA and 07C were chosen and tested as leading potential germination
inhibitors for this specific aim. The germination assay also allowed for compound
potency testing to investigate whether the compounds are inhibitors or
promotors of spore germination for each C. difficile strain at varying
concentrations.
From the in vitro analyses, testing of the compounds against various strains
in vivo was the next specific aim. The mice model was used to observe animals
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for signs for CDI. The mice model also allowed for visual observation of more
subtle differences between infection symptoms of CDI caused by the different
strains. Mice symptoms severities were scored via a CDI rubric. Mice that
received spores only were compared to those that received spores and
compound treatment.
The hypothesis of this study is that the behavior of CamSA and 07C
against the various C. difficile strains in vitro may give insight into their ability to
prevent CDI in the animal model. Moreover, prophylactic treatment of CDI
through these CamSA analogs can act as molecular probes to target C.
difficile’s spore germination pathway.
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CHAPTER 2
IN VITRO STUDIES:
GERMINATION PROFILES OF CLOSTRIDIUM DIFFICILE CLINICAL ISOLATES
2.1 Introduction
In 2011, Tenover et al. typed 350 toxigenic strains of C. difficile from seven
laboratories in the United States and Canada.135 The strains were organized by
three molecular typing techniques: PCR-ribotyping, pulsed-field gel
electrophoresis (PFGE), and restriction endonuclease analysis (REA).135 Of the
strains that were typed, approximately 70% were of known PCR-ribotypes, 54%
were of known PFGE groups, and 70% were of 1 of 8 common REA groups.135
Some isolates typed using one method also overlapped with clusters from the
other typing methods, while others did not. Therefore, using more than one
typing method can give a more comprehensive outlook on the epidemiology of
the rising diversity of C. difficile strains and their roles in CDI.
Some categories of isolates may display other unique characteristics such
as the higher prevalence in specific geographical regions.83,131,136-138 For
example, a Southern Taiwanese study found that C. difficile ribotypes 017 and
078 were predominant among toxigenic clinical isolates from stools collected
from medical wards of the district hospital in the area.138 Similarly, rising
prevalence of C. difficile ribotype 078 was found in hospital settings in Europe
and the United States.131,158 Ribotype 078 isolates found in Canada were,
however, more prevalent among cattle and swine than in humans.131,159,160
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Some groups of isolates also exhibit resistance to certain anti-microbial
agents and genome alterations that confer hypervirulence. Of interest are the
C. difficile BI/NAP1/027 strains. BI refers to the BI group based on REA, NAP1 is the
North American pulsed-field type 1 based on PFGE, and 027 is the PCR-ribotype.
BI/NAP1/027 strains were isolated from several hospital facilities around North
America and Europe. Strains of PCR-ribotype 027 have been linked with
fluoroquinolone antibiotic resistance.83,161 Although fluoroquinolone antibiotics
are not commonly prescribed to treat CDI, BI/NAP1/027’s resistance to them
have been thought to be a factor in its epidemic spread and
hypervirulence.83,162 One PCR-ribotype 027 strain called R20291 caused recent
CDI epidemics in Europe and North America.133 Strain R20291 as well as other
PCR-ribotype 027 strains have been deemed “hypervirulent” as they were
involved in cases of severe diarrhea, high mortality rates, and high
recurrences.133,163-165 Moreover, PCR-ribotype 027 isolates have been found to
have 234 additional genes compared to type strain 630 (epidemic type X, PCRribotype 012).166 A deletion at position 117 of the tcdC gene (responsible for
repression of toxin A and B production) has been implicated as the cause of
increased toxin production in BI/NAP1/027 strains.83,166,167
As the vehicle for infection, studying how spores germinate is important to
understanding how diverse strains cause CDI. One method used to explore
spore germination is by exploiting their unique property of optical density loss.168170

Spores are optically dense structures. Upon hydration of the spore core and
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degradation of the spore coat, the spore loses its natural refractility, and thus
loses optical density. This can be observed by spectrophotometry.
By employing optical density methods, Heeg et al. mapped the
germination profiles of spores from various C. difficile clinical isolates including
from strain R20291.171 Although some strains displayed expected germination in
the presence of the natural germinant taurocholate (TC) and germination
inhibition in the presence of the natural inhibitor chenodeoxycholate (CDCA),
some strains (R20291, 8085054, CDC 38, DH1834, and 7004578) interestingly
displayed some germination in the presence of 2 mM CDCA when incubated
with 0.1% TC in supplemented brain heart infusion (BHIS) (Table 2.1).155,171 In
contrast, strain 05-1223-046, exhibited high germination when incubated with
0.1% TC in BHIS. Although no unusual germination pattern arose with strain
9001966, it was unable to replicate on BHIS media without TC
supplementation.171 Due to their unique germination and growth profiles, seven
of these strains, along with type strain 630, were used in this thesis study (Table
2.2).171
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Table 2.1. Percentage loss of spore optical density of select C. difficile clinical isolates.

Strain

0.1% TC

2 mM CDCA

BHIS

9001966

47%

3%

11%

8085054

72%

13%

38%

CDC 38

42%

12%

6%

DH1834

58%

57%

27%

05-1223-046

74%

0%

38%

7004578

46%

30%

7%

Spore were heat treated at 60°C for 25 minutes, then incubated with either 0.1%
TC in BHIS, 0.1% TC with 2 mM CDCA in BHIS, or BHIS only. Data from this table was
obtained by Heeg et al. 2012.171

Table 2.2. C. difficile clinical isolates used in this thesis study.

Strain

PCR-Ribotype

Country of Origin

9001966

002

The Netherlands

630

012

Switzerland

8085054

014

The Netherlands

CDC 38

027

USA

DH1834

027

East of England, Ipswich, UK

R20291

027

Stoke Mandeville, UK

05-1223-046

027

Belgium

7004578

078

The Netherlands
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Previously, CamSA has only been tested as an anti-germinant against
strain 630. When incubated with 6 mM TC and 12 mM glycine, CamSA was able
to prevent strain 630 spore germination with a half maximal inhibitory
concentration (IC50) of 58.3 μM.100 In recent preliminary studies performed in the
Abel-Santos Laboratory, CamSA was unable to prevent spore germination in the
hypervirulent strain R20291 at concentrations up to100 μM. Because of this
drawback, the Abel-Santos Laboratory screened over 200 other bile salt analogs
as potential anti-germinants against multiple C. difficile strains. From these
screens, we found some anti-germinant candidates that had IC50 values smaller
than CamSA against strain R20291. The best anti-germinant, compound 07C,
prevented spore germination in both strain 630 and strain R20291 at
concentrations below 100 μM. The goal of this project is to examine the effects
of CamSA and 07C on the spore germination of eight selected C. difficile strains.
The compounds’ abilities to prevent spore germination in vitro will give insight
into possible in vivo effects.

2.2 Materials and Methods
2.2.1 Materials
C. difficile strains R20291, 9001966, 05-1223-046, CDC 38, DH1834, 7004578,
and 8085054 were generously donated by Professor Nigel Minton at the
University of Nottingham in Nottingham, United Kingdom. C. difficile strain 630
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was purchased from the American Type Culture Collection (ATCC). Synthesized
bile salt analogs were provided by Professor Steven M. Firestine at Wayne State
University in Detroit, Michigan, or were previously synthesized in the Abel-Santos
Laboratory.

2.2.2 C. difficile Sporulation
C. difficile cells from a stock culture, frozen in 25% glycerol in brain heart
infusion (BHI) broth supplemented with 0.5% yeast, were streak plated onto BHI
agar supplemented with 2% yeast extract, 0.1% L-cysteine-HCl, and 0.05%
sodium taurocholate (BHIS) to yield single-cell colonies.52 After 48 hours, a single
colony was inoculated into BHI broth supplemented with 0.5% yeast extract and
incubated for 48 hours. The inoculated broth was then spread plated onto BHI
agar prepared as described above. Inoculated plates were incubated for 7
days at 37°C in an anaerobic chamber (10% CO2, 10% H2, 80% N2).

2.2.3 C. difficile Spore Harvest and Purification
Prior to harvesting spores, inoculated plates were flooded with ice-cold
deionized (DI) water. Cells and spores were then harvested by scraping bacteria
colonies from the plates. The harvested cells and spores were pelleted via
centrifugation at 8,000 × g for 5 minutes. The mixture was then resuspended in DI
water and pelleted again. This washing step was repeated twice more. After the
three washing steps, the mixture was centrifuged through a 20% (5 mL) to 50%
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(10 mL) HistoDenz™ gradient at 18,200 × g for 30 minutes with no brake (Figure
2.1).172 As dense structures, only spores can penetrate through the 50%
HistoDenz™ layer to form a thick pellet at the bottom of the centrifuge tube,
while vegetative cells and small fragments of incidentally scraped off agar are
lighter, consequently remaining above the 20% HistoDenz™ layer. The pelleted
spore was then transferred to a clean centrifuge tube where it is washed five
more times before being stored in DI water at 4°C. To determine spore purity,
selected samples were stained using Schaeffer-Fulton endospore staining
method or were visualized via phase contrast microscopy (discussed further in
section 2.2.4).173-175 Spore preparations used were greater than 95% pure after
centrifugation through the HistoDenz™ gradient (Figure 2.2).

20% HistoDenz™
50% HistoDenz™

Centrifugation
18,200 × g
30 min

Cell debris

Spores

Figure 2.1. Spore purification via HistoDenz™ gradient.
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Figure 2.2. Schaeffer-Fulton endospore stain of harvested C. difficile spores. Harvested C.
difficile strain 630 spores (green) after centrifugation through HistoDenz™ gradient shows >
95% purity as observed through light microscopy.

2.2.4 C. difficile Spore Visualization
C. difficile spores and cells were visualized before and after spore harvest
via light microscopy. Two microscopic visualization methods were used to
determine the presence and number of spores: Schaeffer-Fulton endospore
staining method and phase contrast microscopy.

2.2.4.1 Endospore Staining Technique
The Schaeffer-Fulton method is an endospore staining technique that
utilizes malachite green and safranin to differentiate endospores from
vegetative cells (Figure 2.3).173 In the Schaeffer-Fulton method, a small inoculum
of bacteria is placed in a glass microscope slide and mixed with a drop of DI
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water using an inoculating loop. The inoculum is air dried, then heat fixed to the
slide by waving the slide over a flame three to five times. A small porous paper is
then placed over the slide and is drenched with the primary stain malachite
green. The endospore is forced to uptake malachite green by heat from an
open flame for 5 minutes. The heat acts as a mordant to fix the malachite green
to the spores. The excess malachite green is washed from the slide with DI water
for 10-20 seconds to decolorize vegetative cells. Vegetative cells are then
counterstained with safranin for 30 seconds. Endospores and vegetative cells
can be visualized under a light microscope at 1000x magnification. Endospores
will appear green and vegetative cells appear pink (Figure 2.4).
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Figure 2.3. Representation of Schaeffer-Fulton endospore staining technique. Heat-fixed
bacteria are stained with the primary stain malachite green (Step 1). Heat is applied to the
bacteria while malachite green is continuously added for 5 minutes to allow the dye to
penetrate spores and become retained (Step 2). Excess dye is washed with water for 10-20
seconds resulting in the decolorization of vegetative cells (Step 3). The secondary stain
safranin is added for 30 seconds to counterstain vegetative cells (Step 4). Vegetative cells will
appear pink while spores appear green under light microscopy.
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spore

vegetative cell

Figure 2.4. Schaeffer-Fulton endospore stain of C. difficile strain 630. Spores (green) were
stained with malachite green. Vegetative cells (pink) were counterstained with safranin.

2.2.4.2 Phase Contrast Microscopy
Endospores can also be visualized using phase contrast microscopy.174,175
This method does not require staining, but requires a specialized phase contrast
lens to detect differences between vegetative cells and spores. Due to their
high refractive index, dormant spores show as bright structures, while
germinated spores and vegetative cells appear as dark structures.174 A small
inoculum of bacteria is placed on a glass microscope slide and mixed with a
drop of DI water using an inoculating loop as described in 2.2.4.1. A glass cover
slip is placed over the bacteria sample. The slide is viewed under the 1000x
magnification phase contrast microscope lens. Under the phase contrast lens,
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endospores will appear to glow with a halo of light surrounding them, which is
caused by diffracted light passing through the structures (Figure 2.5).

Figure 2.5. Phase contrast microscopy of C. difficile strain 630 spores. Only spores appear to
have the characteristic surrounding glowing halo.

2.2.5 Preparation of Spore Germination Assay
Spores were washed three times with DI water, then heat shocked at 68°C
for 30 minutes. The heat shocking process both kills vegetative cells that may be
present within the spore suspension and heat-activates spores so that they
become more responsive to germinants.176-178 After heat-shock, spores were
washed an additional three times. Heat-shocked spores were resuspended into
germination buffer (0.1 M sodium phosphate buffer supplemented with 0.5%
sodium bicarbonate and adjusted to pH 6.0) to reach an optical density at 580
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nm (OD580) of 1.00. Optical density was measured using a Thermo Scientific
Spectronic Genesys™ 10 Bio UV-Vis spectrophotometer using germination buffer
as a blank.
Stock solutions were prepared in either DMSO or H2O. A 120 mM sodium
taurocholate solution was prepared in DMSO. A 480 mM glycine solution was
prepared in H2O. Other bile salt analogs were also prepared at various
concentrations in DMSO.
The spore germination assays were performed in 96-well plates (Figure
2.6). All experiments were done in triplicate. As negative germination controls,
spores were treated with neat DMSO. As positive germination controls, spores
were treated with 6 mM of sodium taurocholate and 12 mM of glycine. To test
for spore germination inhibition, bile salt analogs were added at different
concentrations to spores. Co-germinant solutions were then pipetted into wells
containing the experimental groups for a final concentration of 6 mM of sodium
taurocholate and 12 mM of glycine.
Following the addition of compound, 180 μL of spores in germination
buffer (OD580 = 1.00) were added to each well. The final volume in each well
was 200 μL. Optical density over time was read by a Labsystems iEMS Reader MF
plate reader using Ascent™ software or a Tecan Infinite M200 plate reader using
Tecan i-control™ software.
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Figure 2.6. Example of a plated 96-well plate used for the spore germination assay.
Experiment was done in triplicate. Blue wells (A1-A3) are the negative germination controls
containing only spores and DMSO. Orange wells (A4-A6) are the positive germination controls
containing only spores and co-germinants taurocholate and glycine. The green wells (A7-H9)
are the experimental groups containing spores, germinants (taurocholate and glycine), and
increasing concentrations of bile salt analogs.

2.2.6 Analysis of Spore Germination and Inhibition Properties
Data obtained following experimental run were transferred to Microsoft
Excel for preliminary data analysis. Optical density change over time was
graphed (Figure 2.7). Optical density readings that did remain the same (at
OD580 = 1.00) over the course of the experiment indicated spores that did not
germinate.87,88,168,169 In contrast, decreasing optical density correlated with spore
germination. 87,88,168,169
Preliminary data analysis allowed for the inhibitory concentration ranges
of the bile salt analog compounds against each C. difficile strain to be
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determined. Following determination of inhibitory concentration ranges,
intermediate concentrations (minimum of 9 values) were used to determined
percent (%) germination by comparing the slope from the germination curves of
each concentration of bile salt analog to the slope from the germination curve
of the positive germination control. The slopes were taken from the linear
portions of each concentration curve from the germination assay kinetic graphs
at around the same timeframe (approximately before 50-60 minutes elapsed
time) (Figure 2.7). Germination kinetic graphs containing the concentrations of
bile salt analogs used to construct dose-dependent curves to determine IC50
values are included in Figures S1-S6, Appendix.
The bile salt analog concentrations with their respective percent
germination values were then transferred to SigmaPlot Version 11 or SigmaPlot
Version 13 and fitted with the four-parameter logistic function to obtain dosedependent curves used to determine the IC50 values for anti-germinant
compounds.179,180 Adjusted R2 values from the regression analyses were above
0.95. IC50 values represent the amount of compound required to reduce spore
germination rate to half the maximal value and are used to compare inhibitory
potency of bile salt analogs.100,179,180 Compounds that had IC50 values under 100
μM were considered active inhibitors, whereas, compounds that had IC50 values
above 100 μM were deemed inactive.
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Figure 2.7. Example of a germination assay kinetic graph measuring optical density change
over time. The blue line represents the negative germination control in which no germination
occurs (no loss in optical density). The orange line represents the positive germination control
in which spores are germinating (losing optical density) over time. The area in the red box
represents the linear portion of the curve that will be used to determine the slope of the
positive germination control. The ratio of experimental group slope to the positive
germination control slope will determine percent spore germination.

2.2.7 C. difficile PCR Confirmation
When necessary, polymerase chain reaction (PCR) was used to amplify
specific segments of genomic DNA. DNA band analysis via 1% agarose gel
electrophoresis confirmed the presence or absence of C. difficile. Specific
forward and reverse primers were used to detect C. difficile and consider the
possibility of C. sordellii contamination (another Clostridium species used in the
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Abel-Santos Laboratory). Primers were ordered from Integrated DNA
Technologies (IDT). Primers, 2.5 μL of each, were added to 1 μL of genomic DNA,
then mixed with 6.5 μL of water and 12.5 μL of Lucigen EconoTaq® PLUS 2x
Master Mix containing EconoTaq DNA polymerase, dNTPs, MgCl2, a PCR
enhancer, and reaction buffer, for a final volume of 25 μL. DNA was denatured
at 94°C annealed at 50°C, and extended at 68°C in a Bio-Rad MyCycler™
Thermal Cycler.
Following amplification, 5 μL of each sample of PCR contents [mixed with
1 μL of 6x loading dye] was added to individual wells of a 1% agarose gel
prepared with 1x TAE (Tris-acetate-EDTA) buffer and stained with 0.5 μg/mL
ethidium bromide (EtBr) to act as a fluorescent tag. Gel electrophoresis was run
for 20 minutes at a voltage of 135 V, current of 500 mA, and wattage of 250 W.
DNA bands were analyzed using the UVP VisionWorks®LS Analysis Software and
the UVP EC3 Imaging System. A Promega BenchTop 1kb DNA ladder was used
for reference markers.

2.3 Results and Discussion
2.3.1 Germination Profile of strain 630
Both CamSA and 07C were able to prevent germination of C. difficile
strain 630 spores. The IC50 value of CamSA against strain 630 was previously
determined to be 58.3 μM.100 Therefore, this germination assay was only used to
confirm that CamSA could prevent spore germination at around that same
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concentration (Figure 2.8). At 50 μM CamSA, 31% of spore germination was
inhibited.
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Figure 2.8. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain 630 spores. Spores were resuspended in germination buffer and treated with
neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and glycine (12
mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50 μM CamSA
(■), 6.25 μM 07C (♦), and 50 μM 07C (●). In actuality, more concentrations of bile salt analogs
were used and data was collected every minute for 120 minutes (Figure S1, Appendix). For
clarity, select concentrations are represented and data at five minute intervals are shown.
The data points indicate the means from three independent measures (n = 3) and the error
bars signify standard deviation from the mean.

07C was found to be a better germination inhibitor than CamSA by 7-fold
against strain 630. Spores were treated with 6 mM taurocholate and 12 mM
glycine and added to various concentrations of 07C (Figure 2.8). At 6.25 μM
07C, 39% of spore germination was inhibited. At 50 μM 07C, spore germination
was mostly inhibited. The IC50 of 07C against strain 630 was determined to be
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8.19 μM by regression analysis of a dose-dependent curve (Figure 2.9). The
adjusted R2 for this curve was 0.9654.

Figure 2.9. IC50 calculation for 07C against C. difficile strain 630 spores. The graph represents
the dose-response curve of strain 630 spores germinated with fixed concentrations of
taurocholate (6 mM) and glycine (12 mM) added to various concentrations of 07C. The IC 50
value of 07C obtained from this regression is 8.19 μM. The germination assay kinetic graph
that includes the 07C concentrations used to determine this IC50 value can be found in Figure
S1, Appendix.

2.3.2 Germination Profile of strain R20291
The germination assay for the hypervirulent strain R20291 displayed unique
results. Contrary to expectation, CamSA was unable to prevent germination of
strain R20291 spores. At 50 μM CamSA, spores germinated at about the same
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rate as the positive germination controls containing only taurocholate and
glycine (Figure 2.10). Moreover, up to 1000 μM CamSA, spore germination was
comparable to the positive germination control. It is possible that CamSA might
be able to prevent loss in optical density of strain R20291 spores, but may require
higher concentrations in the millimolar range.
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Figure 2.10. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain R20291 spores. Spores were resuspended in germination buffer and treated with
neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and glycine (12
mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50 μM CamSA
(■), 1.5625 μM 07C (▲), 6.25 μM 07C (♦), and 25 μM 07C (●). In actuality, more concentrations
of bile salt analogs were used and data was collected every minute for 120 minutes (Figure
S2, Appendix). For clarity, select concentrations are represented and data at five minute
intervals are shown. The data points indicate the means from three independent measures (n
= 3) and the error bars signify standard deviation from the mean.
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Although CamSA was unable to prevent germination of strain R20291
spores, 07C prevented spore germination even at low micromolar
concentrations (Figure 2.10). At just 1.5625 μM 07C, 43% of spore germination
was inhibited. At 25 μM 07C, spore germination was inhibited by 87%. Regression
analysis from a dose-dependent curve revealed an IC50 of 1.92 μM for 07C
against strain R20291 with an adjusted R2 of 0.9922 (Figure 2.11).

Figure 2.11. IC50 calculation for 07C against C. difficile strain R20291 spores. The graph
represents the dose-response curve of strain R20291 spores germinated with fixed
concentrations of taurocholate (6 mM) and glycine (12 mM) added to various
concentrations of 07C. The IC50 value of 07C obtained from this regression is 1.92 μM. The
germination assay kinetic graph that includes the 07C concentrations used to determine this
IC50 value can be found in Figure S2, Appendix.
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2.3.3 Germination Profile of strain 9001966
Similar to strain R20291, strain 9001966 spores were able to germinate in
the presence of CamSA (Figure 2.12). Up to 100 μM CamSA, loss of optical
density remained nearly the same as the positive germination control. Since the
cutoff for inhibition activity was set at 100 μM, CamSA was deemed inactive
against strain 9001966.
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Figure 2.12. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain 9001966 spores. Spores were resuspended in germination buffer and treated
with neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and
glycine (12 mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50
μM CamSA (■), 6.25 μM (▲), 25 μM 07C (♦), and 50 μM 07C (●). In actuality, more
concentrations of bile salt analogs were used and data was collected every minute for 120
minutes (Figure S3, Appendix). For clarity, select concentrations are represented and data at
five minute intervals are shown. The data points indicate the means from three independent
measures (n = 3) and the error bars signify standard deviation from the mean.
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Germination inhibition of strain 9001966 spores required higher
concentrations of 07C than strain R20291. Like, strain 630, 07C was able to inhibit
spore germination at similar concentrations (Figure 2.12). At 6.25 μM 07C, 42% of
spore germination was inhibited. The IC50 for 07C against strain 9001966 was
found to be 7.60 μM with an adjusted R2 of 0.9915 (Figure 2.13).

Figure 2.13. IC50 calculation for 07C against C. difficile strain 9001966 spores. The graph
represents the dose-response curve of strain 9001966 spores germinated with fixed
concentrations of taurocholate (6 mM) and glycine (12 mM) added to various
concentrations of 07C. The IC50 value of 07C obtained from this regression is 7.60 μM. The
germination assay kinetic graph that includes the 07C concentrations used to determine this
IC50 value can be found in Figure S3, Appendix.
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2.3.4 Germination Profile of strain 05-1223-046
C. difficile strain 05-1223-046 displayed a strikingly different germination
profile than the majority of tested strains. As expected, strain 05-1223-046 did not
lose optical density when incubated with neat DMSO. Despite this, strain 051223-046 was also unable to germinate in the presence of 6 mM taurocholate
with 12 mM glycine (Figure 2.14). After several trials resulting in the same pattern,
we hypothesized that this strain may require a higher concentration of
taurocholate and/or glycine for germination to occur. Regardless of increasing
the concentration of one or both germinants, however, strain 05-1223-046 spores
were still unable to germinate (Figure 2.14). Therefore, inhibition by the bile salt
analog compounds in vitro could not be determined for this strain under these
circumstances.
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Figure 2.14. Effects of taurocholate with glycine on the germination kinetic behavior of C.
difficile strain 05-1223-046 spores. Spores were resuspended in germination buffer and treated
with neat DMSO (○), 6 mM taurocholate with 12 mM glycine (∆), 6 mM taurocholate with 24
mM glycine (□), and 12 mM taurocholate with 24 mM glycine (◊). For clarity, data at five
minute intervals are shown. The data points indicate the means from three independent
measures (n = 3) and the error bars signify standard deviation from the mean.

To rule out contamination, a C. difficile PCR confirmation was performed
(Figure 2.15). Certain forward and reverse primers were chosen to support or
disprove the presence various factors. One pair of primers was for the putative
conjugative transposon protein Tn5397, which has target sites within C. difficile
strain 630.181-183 Therefore, primers for that target sequence was used to detect
strain 630. The absence of a band for Tn5397 established that the C. difficile
strain present in the sample was not strain 630 (Figure 2.15, Lane 2). The Cs2gp
primers were used to detect the presence of the C. sordellii reference strain
Cs2.184 The absence of a band excluded C. sordellii as a contaminant in the
sample (Figure 2.15, Lane 3). The primers for C. difficile toxin A (tcdA) was used
to detect C. difficile and the universal primer pairs GM3 and GM4 were used to
ample 16S rDNA found in bacteria.185 The appearance of bands for these
sequences confirmed that the sample was C. difficile (Figure 2.15, Lane 4 and
5).
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Figure 2.15. PCR confirmation of C. difficile strain 05-1223-046. PCR products from specific
primers and genomic DNA were analyzed on 1% agarose gel. A 1 kb ladder is used for
reference (Lane 1). The absence of a band for the putative conjugative transposon tn5397
672 confirms the absence of strain 630 (Lane 2). The absence of a band for C. sordellii
reference strain Cs2 gp 927 verifies that C. sordellii contamination is not present in the sample
(Lane 3). Bands for tcdA 1170 (Lane 4) and universal GM3/GM4 16S rDNA (Lane 5) confirm
the presence of C. difficile.

There could be a number possibilities as to why strain 05-1223-046 spores
were unable to germinate with taurocholate and glycine. Perplexingly, in the
Heeg et al. study, strain 05-1223-046 spores lose optical density by 74% when
incubated with 0.1% taurocholate in BHIS.171 In that preparation, glycine was not
added as a co-germinant. One hypothesis is that glycine may not be the most
suitable co-germinant for spore germination of this particular strain. In a study by
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Howerton, Ramirez, and Abel-Santos, several other amino acid analogs were
able to induce germination of strain 630 spores to different degrees.100
Individually, the amino acids were unable to trigger spore germination, but as a
cocktail or in addition to taurocholate, spore were able to elicit germination.100
Testing different possible co-germinants in the germination of strain 05-1223-046
may be the next step in determining optimal germination conditions as well as
discovering whether our proposed bile salt analog compounds can inhibit spore
germination of that strain.

2.3.5 Germination Profile of strain CDC 38
C. difficile strain CDC 38 spores were able to germinate in the presence of
CamSA. Up to 100 μM CamSA, spores germinated at the same rate as the
positive germination control containing taurocholate and glycine (Figure 2.16).
Therefore, based on the cutoff criteria, CamSA is not considered to be an active
germination inhibitor at concentrations below 100 μM.
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Figure 2.16. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain CDC 38 spores. Spores were resuspended in germination buffer and treated
with neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and
glycine (12 mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50
μM CamSA (■), 1.5625 μM 07C (▲), 6.25 μM 07C (♦), and 50 μM 07C (●). In actuality, more
concentrations of bile salt analogs were used and data was collected every minute for 120
minutes (Figure S4, Appendix). For clarity, select concentrations are represented and data at
five minute intervals are shown. The data points indicate the means from three independent
measures (n = 3) and the error bars signify standard deviation from the mean.

Compound 07C greatly inhibited strain CDC 38 spore germination at low
micromolar concentrations (Figure 2.16). At 1.5625 μM 07C, 79% of spores
germinated. Only 43% of spores germinated at 6.25 μM. At 12.5 μM 07C,
germination was inhibited by 77%. The IC50 for 07C against the CDC 38 isolate
was calculated to be 4.62 μM with an adjusted R2 of 0.9897 (Figure 2.17).
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Figure 2.17. IC50 calculation for 07C against C. difficile strain CDC 38 spores. The graph
represents the dose-response curve of strain CDC 38 spores germinated with fixed
concentrations of taurocholate (6 mM) and glycine (12 mM) added to various
concentrations of 07C. The IC50 value of 07C obtained from this regression is 4.62 μM. The
germination assay kinetic graph that includes the 07C concentrations used to determine this
IC50 value can be found in Figure S4, Appendix.

2.3.6 Germination Profile of strain DH1834
Like the other tested isolates aside from strain 630, CamSA was unable to
prevent spore germination of strain DH1834 (Figure 2.18). At 50 μM CamSA, spore
germination resulted at a similar rate to the positive germination control. Even at
100 μM CamSA, comparable germination was exhibited. Thus, CamSA is not
considered to be an active inhibitor against spores of this strain.
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Figure 2.18. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain DH1834 spores. Spores were resuspended in germination buffer and treated with
neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and glycine (12
mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50 μM CamSA
(■), 1.5625 μM 07C (▲), 6.25 μM 07C (♦), and 50 μM 07C (●). In actuality, more concentrations
of bile salt analogs were used and data was collected every minute for 120 minutes (Figure
S5, Appendix). For clarity, select concentrations are represented and data at five minute
intervals are shown. The data points indicate the means from three independent measures (n
= 3) and the error bars signify standard deviation from the mean.

Germination inhibition was, however, evident with micromolar
concentrations of 07C (Figure 2.18). At 1.5625 μM 07C, spore germination was
down to 74%. At 50 μM 07C, loss of optical density was comparable to the
negative germination control containing only DMSO and spores in germination
buffer. Compound 07C’s IC50 against strain DH1834 is 4.15 μM with an adjusted
R2 of 0.9720.
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Figure 2.19. IC50 calculation for 07C against C. difficile strain DH1834 spores. The graph
represents the dose-response curve of strain DH1834 spores germinated with fixed
concentrations of taurocholate (6 mM) and glycine (12 mM) added to various
concentrations of 07C. The IC50 value of 07C obtained from this regression is 4.15 μM. The
germination assay kinetic graph that includes the 07C concentrations used to determine this
IC50 value can be found in Figure S5, Appendix.

2.3.7 Germination Profile of strain 7004578
C. difficile strain 7004578 sporulated poorly on BHIS agar. Hence, this strain
was sporulated on C. difficile sporulation media (SMC) agar containing 90 g
Bacto peptone, 5 g proteose peptone, 1 g (NH4)2SO4, 1.5 g Tris base, 15 g agar
powder, and 5 g yeast per liter.186-188 All other sporulation conditions remained
the same.
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Oddly, spores of strain 7004578 were only able to germinate nominally in
the presence of 6 mM taurocholate and 12 mM glycine. Spores, however, did
not germinate in the negative germination control with DMSO. Like with strain
05-1223-046, we tested the effects of different concentrations of taurocholate
and glycine on germination (Figure 2.20). Unlike with strain 05-1223-046, strain
7004578 spores germinated more when the concentrations of taurocholate and
glycine were doubled. Loss of optical density, however, occurred to a much
lesser degree than what was observed with other strains. Because optical
density was only decreased by less than 10%, detecting slight changes in
germination rates using multiple small concentrations of bile salt analog
compounds would not be ideal for calculating IC50. Hence, the effects of
CamSA and 07C on strain 7004578 spore germination could not be determined.
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Figure 2.20. Effects of taurocholate with glycine on the germination kinetic behavior of C.
difficile strain 7004578 spores. Spores were resuspended in germination buffer and treated
with neat DMSO (○), 6 mM taurocholate with 12 mM glycine (∆), 6 mM taurocholate with 24
mM glycine (□), and 12 mM taurocholate with 24 mM glycine (◊). For clarity, data at five
minute intervals are shown. The data points indicate the means from three independent
measures (n = 3) and the error bars signify standard deviation from the mean.

As with strain 05-1223-046, a PCR was run to confirm the presence of C.
difficile. The same primers used for strain 05-1223-046’s PCR confirmation was
used for strain 7004578 (see section 2.3.3). No C. sordellii contamination was
found in the strain 7004578 sample (Figure 2.21, Lane 3). Moreover, the sample
was confirmed to be C. difficile based on the presence of bands for both tcdA
and 16S rDNA (Figure 2.21, Lane 4 and 5).
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Figure 2.21. PCR confirmation of C. difficile strain 7004578. PCR products from specific primers
and genomic DNA were analyzed on 1% agarose gel. A 1 kb ladder is used for reference
(Lane 1). The absence of a band for the putative conjugative transposon tn5397 672 confirms
the absence of strain 630 (Lane 2). The absence of a band for C. sordellii reference strain Cs2
gp 927 verifies that C. sordellii contamination is not present in the sample (Lane 3). Bands for
tcdA 1170 (Lane 4) and 16S rDNA (Lane 5) confirm the presence of C. difficile.

Since PCR confirmed that the sample was C. difficile, another possibility as
to why the spores had trouble germinating was the SMC agar used to
sporulation strain 7004578. To test this, a germination assay of strain 630
sporulated using SMC agar was performed and compared to a germination
assay of strain 630 sporulated using BHIS agar. The assay revealed that spores of
strain 630 that were sporulated on SMC agar were able to germinate normally
when incubated with 6 mM taurocholate and 12 mM glycine. Although the
relative optical density loss slightly differed between spores sporulated on BHIS
agar versus SMC agar, the rate of germination remained the same. Therefore, it
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is concluded that the SMC agar media was not responsible of strain 7004578’s
failure to germinate.
The choice of amino acid co-germinant could be a factor in the
germination of strain 7004578 spores. Although doubling the concentrations of
taurocholate and glycine did lower optical density slightly, the cause of this
could be due to the doubling of the taurocholate itself since doubling of the
glycine concentration alone had no difference in optical density loss compared
to 6 mM taurocholate and 12 mM glycine data (Figure 2.20). If this were the
case, taurocholate was still only able to induce germination minimally. A
different amino acid co-germinant may be needed for optimal germination of
this strain. This will be explored further in future studies.

2.3.8 Germination Profile of strain 8085054
For C. difficile strain 8085054 spores, CamSA was not an active inhibitor.
Spore germination failed to be inhibited at 50 μM CamSA (Figure 2.22). Although
CamSA may be active at much higher concentrations, it was not active with
less than 100 μM.
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Figure 2.22. Effects of germinants and inhibitors on the germination kinetic behavior of C.
difficile strain 8085054 spores. Spores were resuspended in germination buffer and treated
with neat DMSO (○) or treated with a fixed concentration of taurocholate (6 mM) and
glycine (12 mM) added to final concentrations of 0 μM of bile salt analog compound (∆), 50
μM CamSA (■), 1.5625 μM 07C (▲), 6.25 μM 07C (♦), and 50 μM 07C (●). In actuality, more
concentrations of bile salt analogs were used and data was collected every minute for 120
minutes (Figure S6, Appendix). For clarity, select concentrations are represented and data at
five minute intervals are shown. The data points indicate the means from three independent
measures (n = 3) and the error bars signify standard deviation from the mean.

Compound 07C appeared to be active against strain 8085054 at low
micromolar concentrations (Figure 2.22). At just 1.5625 μM 07C, 54% of spore
germination was inhibited. The IC50 of 07C against strain 8085054 is 1.28 μM with
an R2 of 0.9880 (Figure 2.23).
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Figure 2.23. IC50 calculation for 07C against C. difficile strain 8085054 spores. The graph
represents the dose-response curve of strain 8085054 spores germinated with fixed
concentrations of taurocholate (6 mM) and glycine (12 mM) added to various
concentrations of 07C. The IC50 value of 07C obtained from this regression is 1.28 μM. The
germination assay kinetic graph that includes the 07C concentrations used to determine this
IC50 value can be found in Figure S6, Appendix.

2.3.9 Comparison of Germination Profiles Among All Tested C. difficile Strains
A total of eight C. difficile strains were tested for their responses to bile salt
analog compounds CamSA and 07C. Although there are several similarities
among the germination profiles of the strains, there are also some striking
differences. These comparisons include differing responses to the germinants
taurocholate and glycine and varying activity of bile salt analogs against each
testable strain (Table 2.3).
77

Table 2.3. Comparison of germination profiles among all tested C. difficile strains.

Strain

CamSA IC50

07C IC50

630

58.3 μM*

8.19 μM

R20291

> 100 μM

1.92 μM

9001966

> 100 μM

7.60 μM

05-1223-046

TBD

TBD

CDC 38

> 100 μM

4.62 μM

DH1834

> 100 μM

4.15 μM

7004578

TBD

TBD

8085054

> 100 μM

1.28 μM

TBD denotes IC50 values that are yet to be determined for
compounds where spores of those C. difficile strains were
unable to germinate in the presence of 6 mM taurocholate and
12 mM glycine. Modifications will be made to determine
potential co-germinants and conditions needed to promote
germination in those strains.
*Value was obtained from Howerton, Ramirez, and Abel-Santos
2011.100

All strains did not germinate in the neat DMSO negative germination
control. Six of the eight strains were able to germinate with 6 mM taurocholate
and 12 mM glycine as expected. These concentrations were chosen after
previous research showed that they were optimal for germination of strain 630
and appropriate for germination inhibition studies.100 Those six strains observed
loss of optical density by 30%-50% when incubated with taurocholate and
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glycine. Therefore, measuring IC50 values for those strains was possible as long as
germination rates corresponded to varying concentrations of compounds.
However, strains 05-1223-046 and 7004578 spores failed to exhibit the same
decrease in optical density as the other tested strains. After the possibilities of
contamination and increasing concentrations were eliminated, it is
hypothesized that other molecules may act as co-germinants of these two
strains. Both strains are different PCR-ribotypes: 027 for strain 05-1223-046 and 078
for strain 7004578. Although no other 078 strains were tested, other 027 strains did
not exhibit the same issue as 05-1223-046. Also, strain 7004578 spores were able
to germinate slightly with doubled taurocholate and glycine concentrations, but
strain 05-1223-046 spores were unable to display germinate distinct from the
negative germination control. Future studies will include testing other amino
acids as co-germinants of these two strains. At the conclusion of this part of the
in vitro germination study, the IC50 for these two bile salt analog compounds
against these strains have yet to be determined.
Of the remaining strains that were able to germinate with taurocholate
and glycine, only strain 630 was capable of avoiding spore germination using
less than 100 μM CamSA. A couple other strains were tested up to 1 mM final
concentration of CamSA, but still did not display inhibition. CamSA may still be
an inhibitor of spore germination, but may be weaker and require higher
concentrations against the 6 mM taurocholate and 12 mM glycine. Spores from
four strains (9001966, CDC 38, DH 1834, and 8085054) were tested for inhibition
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using the naturally-occurring inhibitor chenodeoxycholate. Those four strains
exhibited spore germination inhibition with 2 mM chenodeoxycholate. CamSA
may be active against those other strains at concentrations above 1 mM,
though this has not yet been tested.
While CamSA had an IC50 of 58.3 μM against strain 630, 07C had IC50
values of less than 10 μM against all testable strains. With strains R20291 and
8085054 spores, 07C’s IC50 values were less than 2 μM. Compound 07C had IC50
values between 4-5 μM against CDC 38 and DH 1834 isolates. The IC50 of 07C
against strains 630 and 9001966 were between 7-9 μM. With low IC50 values, 07C
may be a promising germination inhibitor in vivo, though other factors may also
contribute to germination in an in vivo environment.

2.4 Conclusions
The diverse germination profiles of each C. difficile isolate reveal a
glimpse of why CDI is such a fast-growing epidemic. While some strains respond
to known germinants, others may require different molecules for germination to
occur. Moreover, germination inhibition via bile salt analogs also vary among
strains. Thus, finding a prophylactic solution for CDI will require a comprehensive
study on C. difficile germination. Withal, the bile salt recognition site on C.
difficile still has yet to be discovered.
In this study, some strains demonstrated typical behavior against known C.
difficile germinants, taurocholate and glycine. However, spores of two strains,
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05-1223-046 and 7004578, failed to germinate with those molecules. Spores of
strain 630 were prevented from germinating in the presence of both CamSA
and 07C; whereas, spores of all other testable strains were only inhibited by 07C.
Of the strains that could germinate in the presence of taurocholate and
glycine, all observed inhibition of spore germination with the compound 07C
with less than 100 μM. Furthermore, those six strains all had IC50 values less than
10 μM. Although CamSA was only able to prevent germination with strain 630
spores with less than 100 μM, it may still be a potential inhibitor with other strains
at higher concentrations that have not been tested at this time. These in vitro
germination profiles may give insight into in vivo prophylactic treatment of CDI
using the bile salt analogs against these different C. difficile strains. In addition,
there may also be possible correlation between IC50 values and CDI symptoms
in vivo.
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CHAPTER 3
IN VIVO STUDIES:
CDI SYMPTOMS IN THE ANIMAL MODEL
3.1 Introduction
Many animal models have been employed to study various aspects and
mechanisms of CDI. Animals involved in CDI studies include, but are not limited
to hamsters, mice, rabbits, guinea pigs, gnotobiotic piglets, Rhesus monkeys,
and even zebrafish embryos.189,190 Furthermore, food animals like pigs and cattle
and companion animals such as dogs and horses have been implicated in CDI
studies, bringing into question foodborne- or animal interaction-related
transmission of disease. 93-95,191,192 The use of in vivo methods also provides insight
into a plethora of host-pathogen interactions such as CDI pathophysiology and
progression in hosts and C. difficile adaptation and colonization within the GI
tract.189
Animal C. difficile induction models aim to examine CDI symptoms in vivo.
The most commonly and traditionally used animal CDI induction model is the
hamster model193-196. The hamster model was first used in antibiotic-associated
colitis studies in the 1970s when several independent studies found links between
antibiotic use, diarrhea, and colitis.8,12-14,193-197 C. difficile was later implicated as
the culprit of the hemorrhagic lesions.197 After pre-treatment with antibiotics such
as clindamycin, hamsters have been shown to be highly sensitive to CDI when
given relatively low dosages of spores.197 Hamsters can elicit fulminant disease to
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lethal within 48 hours.189,197,198 Although both humans and hamsters are
susceptible to CDI after exposure to clindamycin, the disease progression in
hamsters is much more extreme compared to in humans which can range from
asymptomatic to severe symptoms.189 Also, unlike in humans where the site of
infection is in the colon, hamsters CDI occurs in the cecum.189 Hamster models
are also advantageous in studying colonization of C. difficile in the gut.189
The mouse CDI model is a rodent model that has been developed in
recent years.199,200 Mice are widely used as animal models and are less
expensive than hamsters. In contrast to hamsters, mice are highly resistant to CDI
and require a large inoculum of spores to establish significant infection
symptoms.201 Similar to humans, mice symptoms can range from mild to severe
disease signs. Clinical endpoint is slower in mice than in hamsters and lethality
from CDI is less common in mice.189,199 Therefore, mice models are practical for
studying spore shedding from the GI tract. Interestingly, mice that survive CDI
often make a full recovery and do not relapse.157,189,198-200 A 2013 study by
Howerton, Patra, and Abel-Santos showed that CDI-recovered mice did not
show signs of relapse after being given another course of antibiotic treatment
following a 14-day recovery period.157
The Abel-Santos Laboratory has previously tested the bile salt analog
CamSA in both the mouse and hamster CDI models. In the mouse CDI model,
CamSA prevented CDI symptoms in female C57BL/6 mice with a single 50
mg/kg dose given immediately after challenge with C. difficile spores of strain
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630 and strain VPI 10463.157 Additionally, there was no observable toxicity at this
dosage. Moreover, all mice that were treated with three doses of 50 mg/kg
CamSA did not develop signs of CDI; whereas, mice treated with lower dosages
of CamSA eventually developed some signs of CDI or succumbed to disease.157
In the hamster CDI model, female Golden Syrian hamsters treated with 50
mg/kg CamSA showed a delayed onset of CDI symptoms and fatality
compared to untreated hamsters. Treatment with vancomycin (which is
commonly used to treat CDI) further delayed CDI symptoms and clinical
endpoint in hamsters. In both cases, all hamsters eventually became moribund.
However, the pairing of CamSA and vancomycin treatment in the hamster CDI
model has shown synergistic effects in preventing CDI with an 80% survival rate.
In this current study, the mouse CDI model was utilized to test whether
CamSA and 07C can prevent CDI symptoms in mice challenged with spores of
diverse C. difficile strains. The results were also compared to the data obtained
from the in vitro germination profile analysis.

3.2 Materials and Methods
3.2.1 Materials
C. difficile strains R20291, 9001966, 05-1223-046, CDC 38, DH1834, 7004578,
and 8085054 were generously donated by Professor Nigel Minton of the
University of Nottingham. C. difficile strain 630 was purchased from the ATCC.
Synthesized bile salts were provided by Professor Steven M. Firestine of Wayne
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State University A, or were previously synthesized in the Abel-Santos laboratory.
Laboratory Rodent Diet was provided by the University of Nevada, Las Vegas
animal care facility from LabDiet (St. Louis, MO, USA).

3.2.2 Animals
All procedures involving animals in this study were performed in
accordance with the Guide for Care and Use of Laboratory Animals outlined by
the National Institutes of Health. The protocol was reviewed and approved by
the Institutional Animal Care and Use Committee (IACUC) at the University of
Nevada, Las Vegas (Permit Number: R0914-297). Weaned female mice (strain
C57BL/6) were purchased from Charles River Laboratories (Wilmington, MA,
USA). Mice were housed in groups of five per cage at the University of Nevada,
Las Vegas animal care facility. Upon arrival at the facility, mice were allowed to
acclimate for one week prior to the start of experimentation. All bedding,
cages, food, and water were autoclaved prior to housing animals. All postchallenge manipulations were performed within a biosafety level 2 laminar flow
hood.

3.2.3 30-Day Compound Toxicity Regimen
Animals were given 300 mg/kg body weight (BW) of bile salt analog
compound once per day for 30 days to test for possible toxicity. Bile salt analogs
were administered via oral gavage with a total volume of 50 μL per dose. Neat
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DMSO was used as a control in one cage of mice. Another cage of mice was
given CamSA and mice in a third cage was given 07C. Fecal matter was
collected per mice on days 0, 10, 30 for a separate study involving changes in
gut microbiota. Weight changes were recorded on those days. Significant
weight loss was defined as a loss of greater 15% original body weight. Mice were
observed for signs of distress (i.e. lethargy and hunched posture) daily. At the
end of the thirty-day trial, animals were sacrificed and necropsied to investigate
for potential anatomical abnormalities.

3.2.4 Preparation of C. difficile Spores for Infection
C. difficile spores were harvested and purified using the Abel-Santos
Laboratory Method as outlined in section 2.2.5 and section 3.2.3.1. Following
spore purification, colony forming units (CFUs) were determined via plating
methods. C. difficile spore inoculums were then optimized for infection in the
murine CDI model.

3.2.4.1 C. difficile Spore Harvest and Purification
Prior to harvesting spores, inoculated plates were flooded with ice-cold
deionized (DI) water. Cells and spores were then harvested by scraping bacteria
colonies from the plates. The harvested cells and spores were pelleted via
centrifugation at 8,000 × g for 5 minutes. The mixture was then resuspended in DI
water and pelleted again. This washing step was repeated twice more. After the
86

three washing steps, the mixture was centrifuged through a 20% (5 mL) to 50%
(10 mL) HistoDenz™ gradient at 18,200 × g for 30 minutes with no brake (Figure
2.1).172 The pelleted spore was then transferred to a clean centrifuge tube where
it is washed five more times before being stored in DI water at 4°C. Spore purity
was determined via Schaeffer-Fulton endospore staining method or phase
contrast microscopy (see section 2.2.4). Spore preparations used were > 95%
pure after centrifugation through the HistoDenz gradient (Figure 2.2).

3.2.4.2 Determination of Colony Forming Units (CFUs)
Spores were washed three times with DI water, heat shocked at 68°C for
30 minutes, then washed three more times. Heat-shocked spores were
suspended into a fixed volume of DI water before being serially diluted in water.
Serial dilutions were then plated on BHIS agar supplemented with 2% yeast
extract, 0.1% L-cysteine-HCl, and 0.05% sodium taurocholate (prepared as
described in section 2.2.2). Plates were incubated in an anaerobic chamber
(10% CO2, 10% H2, 80% N2) for 48 hours to yield individual colonies. Colonies were
then counted to enumerate colony-forming units (CFUs).

3.2.4.3 Optimization of C. difficile Spore Inoculum for Infection
The murine CDI induction model used in this experiment was adapted
from procedures published by Chen et al. in 2008 (Scheme 3.1).200 Mice were
fed a standard laboratory rodent diet. Mice were given three consecutive days
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of filtered antibiotic cocktail containing kanamycin (0.4 mg/ml), gentamycin
(0.035 mg/ml), colistin (850 U/ml), metronidazole (0.215 mg/ml), and
vancomycin (0.045 mg/ml). Mice were allowed to drink the antibiotic cocktail
ad libitum. Antibiotic cocktail was refreshed daily or as needed. Mice were then
given autoclaved and filtered DI water for the remainder of the experiment. On
the day prior to infection (24 hours before C. difficile challenge), mice were
given an intraperitoneal (IP) injection of 10 mg/kg BW clindamycin. On the day
of infection, mice were challenged with 108 C. difficile spores via oral gavage.
This heavy inoculum of spores (108 CFUs) has been shown to establish severe CDI
with mice challenged with C. difficile strain 630.90 Mice were then observed for

8

10 C. difficile
spores

Antibiotic cocktail

Clindamycin

CDI symptoms for seven days post-challenge (discussed further in section 3.2.5).

Autoclaved H2O for remainder of experiment
Scheme 3.1. Murine CDI induction model adapted from Chen et al. 2008.200 This model also
represents the positive CDI control group regimen (spores only).
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3.2.5 Animal CDI Model Regimens
The murine CDI prevention models used in this experiment were adapted
and slightly modified from procedures published by Howerton, Patra, and AbelSantos in 2013.157 Immediately following challenge, mice received 0 mg/kg BW
or 50 mg/kg BW of one of two synthetic bile salt analogs via oral gavage:
CamSA and 07C. One group of five antibiotic-treated mice was used as a
negative CDI control group and were challenged with only DI water in place of
C. difficile spores (Scheme 3.2). Positive CDI control mice received 108 C. difficile
spores and 0 mg/kg BW of the synthetic bile salt analog (Scheme 3.1).
Experimental groups were challenged with 108 C. difficile spores and received
daily 50 mg/kg of the synthetic bile salt analog compound at 0, 24, and 48 hours

H2O

Antibiotic cocktail

Clindamycin

post-challenge (Scheme 3.3) for a total of three doses.

Autoclaved H2O for remainder of experiment
Scheme 3.2. Negative CDI control group regimen (no spores).
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8

10 C. difficile
spores

Clindamycin

Antibiotic cocktail

Autoclaved H2O for remainder of experiment
Scheme 3.3. Experimental group regimen (spores and bile salt analog). Bile salt analogs
(yellow stars) are given as a single daily dose immediately after challenge, 24 hours postchallenge, and 48 hours post-challenge for a total of 3 doses.

3.2.6 Observation of CDI Symptoms in Animals
Mice were observed for signs of CDI twice daily and were scored
according a CDI scoring rubric (Table 3.1). This rubric has been adapted and
slightly modified from a previously published rubric by Howerton, Patra, and
Abel-Santos in 2013.157 CDI signs included anogenital redness,
lethargic/distressed behavior, presence of diarrhea or soiled bedding, wet tail,
hunched posture, and weight loss.
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Table 3.1. CDI Scoring Rubric for mouse CDI model.

CDI Disease Signs

Score

Pink anogenital area

1

Red anogenital area

2

Lethargy/distress

2

Increased diarrhea/soiled bedding

2

Mild wet tail

1

Wet tail

2

Hunched posture

2

8-15% weight loss

1

> 15% weight loss

2

Adapted and modified from Howerton, Patra, and
Abel-Santos 2013..157

Scores from each animal were tallied to determined severity of CDI
symptoms (Table 3.2). Animals scoring equal to or less than 2 were
undistinguishable from noninfected controls and were considered non-diseased.
Animals scoring 3–4 were considered to have mild CDI. Animals scoring 5–6 were
considered to have moderate CDI. Animals scoring greater than 6 were
considered to have severe CDI and were immediately sacrificed.

Table 3.2. Mouse CDI symptoms severity with corresponding scores.

CDI Symptoms Severity

Score

Non-diseased

≤2

Mild CDI

3-4

Moderate CDI

5-6

Severe CDI (euthanized)

<6
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3.2.7 Statistical Analysis
Severity of symptoms were analyzed via box-and-whisker plots. Data from
the plots were expressed as mean ± standard deviation. Standard deviations
represent a minimum of three independent values (n ≥ 3, where n is one mouse).
A one-tailed unpaired Student’s T-test was performed to determine statistically
significant difference between two means (positive CDI control group versus
experimental group). Statistical significance was determined as P values of < 0.1
(*), < 0.05 (**), or < 0.01 (***).

3.3 Results and Discussion
3.3.1 Observable Toxicity of Bile Salt Analogs in Mice
Of the bile acids present in the gut, approximately 95% of them get
recycled back into enterohepatic circulation.151,152 Some bile salts, such as
chenodeoxycholate, are very readily absorbed by the intestines and brought
back to the liver, while others, such as lithocholate (formed from unabsorbed
chenodeoxycholate), are poorly absorbed and remain in the gut. Although
most of the remaining 5% of bile acids are eliminated through excretion,
accumulation of too much of bile acid like lithocholate can lead to toxic
effects.153 Thus, the two synthetic bile salt analog compounds, CamSA and 07C,
were tested for any toxic effects to mice. Mice were given 300 mg/kg of either
CamSA or 07C every day for thirty days and were observed for signs of toxicity.
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Neat DMSO was used as a control since bile salt analogs were dissolved in
DMSO.
Body weight loss is often used as a measure of toxicity in
pharmacodynamic studies.199,200,202 Weight loss in mice was calculated as
percent change from the weight on day 0. Mice that received neat DMSO, 300
mg/kg CamSA, and 300 mg/kg 07C all did not experience weight loss greater
than 10% over the course of the trial (Figure 3.1). Moreover, mice did not appear
to display signs of distress such as lethargy or having a hunched posture. Mice
activity was monitored for 15-20 minutes after oral gavage every day. Mice
appeared to exhibit normal behavior following oral gavage.
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Figure 3.1. Mean relative percent weight change of mice in bile salt analog toxicity study.
Data points represent mean relative percent weight change compared to day 0 from five
independent measures (n =5). Error bars indicate standard deviation from the mean. A)
Average weight of mice that received neat DMSO daily for thirty days (solid line). B) Average
weight of mice that received 300 mg/kg CamSA daily for thirty days (dotted line). C)
Average weight of mice that received 300 mg/kg 07C daily for thirty days (dashed line).

Furthermore, necropsy was performed to check for anatomical anomalies
that may be caused by the compounds given. Of all fifteen mice tested, only
one mouse in the 300 mg/kg CamSA cage succumbed to death on day 21.
After necropsy of the animal, an air pocket was found in the stomach. This is
most likely due to an oral gavage error when air may have accidentally been
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introduced. No organomegaly or other abnormalities of any other organs were
found, making the cause of death unlikely to be due to compound toxicity.
All other mice survived the entirety of the trial. Upon necropsy, all organs
were intact and no enlargement was discovered. Organ enlargements of
concern included digestive organs such as the liver, pancreas, spleen stomach,
small intestine, and colon. The liver was of interest as it is responsible for recycling
bile salts. Attention was also brought to the intestines as they are the sight of
reabsorption of bile salts. Neither had visibly observable damage or
enlargement. With weight loss, signs of distress, and necropsy surveillance in
consideration, neat DMSO, CamSA, and 07C all appeared to have no
observable toxicity to mice.

3.3.2 Analysis of CDI Symptoms in Mice Challenged with DI Water
One cage of five mice challenged with DI water in place of C. difficile
spores was used as a negative CDI control. These mice did not receive any bile
salt analog compound treatment. Other than incidental weight loss that was
less than 15% original body weight prior to challenge, the mice did not develop
any signs of CDI. Thus, the mice received a maximum score of a 1 indicating no
disease (Figure 3.2).
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Figure 3.2. CDI symptoms severity in mice
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3.3.3 Analysis of CDI Symptoms in Mice Challenged with strain 630
CamSA and 07C both prevented CDI in mice challenged with C. difficile
strain 630. Mice that were challenged with 108 strain 630 spores (positive CDI
control), developed CDI symptoms, though to varying degrees (Figure 3.3A). At
48 hours post-infection, the mean symptoms severity for the positive control
cage was 4.2, indicating mild-to-moderate CDI (Table 3.3). Although one animal
received a score of a 3 (mild CDI), another succumbed to disease with a score
of an 8 (severe CDI). Positive control mice eventually recovered after 72 hours
and were monitored for at least seven more days. No surviving mice exhibited
relapsed CDI.
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Figure 3.3. CDI symptoms severity in mice challenged with strain 630 spores. Data points
represent each animal’s
*** symptoms severity based on the CDI scoring rubric. Overlap of data

points occurs when animals share the
** same score. Error bars indicate standard deviation from
the mean. Standard deviations represent a minimum of three independent values (n ≥ 3).
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Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.

630 Group

24 h

48 h

72 h

96 h

120 h

Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.

Control

2.0

4.2

0.5

0.5

0

CamSA-treated

0

0.2

0.2

0

0.2

07C-treated

0.4

0

0

0

0

KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.
KEY:
KEY: light
light green
green =
= non-disease,
non-disease, yellow-orange
yellow-orange =
= mild-to-moderate
mild-to-moderate CDI
CDI

Compared to the mild-to-moderate CDI found in the untreated mice,
Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.

CamSAwere mostly
asymptomatic.
KEY: light and
green07C-treated
= non-disease,mice
yellow-orange
= mild-to-moderate
CDI Scores of 1 by
individual mice were caused by slight changes in weight which can sometimes
be
an 3.3.
indicator
of symptoms
progressive
CDIfor
when
continues
to630
decrease
Table
Mean CDI
severity
miceweight
challenged
with strain
spores. over a
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

period of time. CamSA-treated mice had a maximum mean score of 0.2,
signifying no disease (Figure 3.3B, Table 3.3). Likewise, 07C-treated mice had a
Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.

maximum mean score of 0.4, also indicative of no CDI (Figure 3.3C, Table 3.3).
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

Thus, both compounds were effective at preventing CDI symptoms in strain 630infected mice at the three 50 mg/kg doses given.

Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

3.3.4 Analysis of CDI Symptoms in Mice Challenged with strain R20291
challenged
withseverity
C. difficile
strain
R20291with
spores
Table Mice
3.3. Mean
CDI symptoms
for mice
challenged
strainexhibited
630 spores.slightly
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

higher CDI scores than strain 630. Untreated positive CDI control mice had a
maximum mean symptoms severity of 5.2 at 48 hours post-infection, indicating
Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.

moderate CDI (Figure 3.4A, Table 3.4). At the lower end, two mice had mild CDI
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

with scores of 4. At the higher end, one mouse became moribund with severe
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Table 3.3. Mean CDI symptoms severity for mice challenged with strain 630 spores.
KEY: light green = non-disease, yellow-orange = mild-to-moderate CDI

CDI, receiving a score of 7. The remaining mice received scores of 5 and 6
(moderated CDI).
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Table 3.4. Mean CDI symptoms severity for mice challenged with strain R20291 spores.

R20291 Group

24 h

48 h

72 h

96 h

120 h

Control

1.0

5.2

2.0

1.25

0.75

CamSA-treated

1.0

4.2

4.75

1.25

0

07C-treated

0

2.0

2.6

0.2

0.6

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow-orange = mild-tomoderate CDI, orange = moderate CDI

CamSA-treated mice were not protected from CDI. At 48 hours, CDI
symptoms in CamSA-treated mice were not significantly different from the
positive control (Figure 3.4B). Although the mean symptoms severity is 4.2 (mildto-moderate CDI) for CamSA-treated mice compared to 5.2 (moderate CDI) in
the positive control, the spread is much larger in the CamSA-treated mice (SD =
2.58 vs. 1.30 in positive control mice) (Table 3.4). This may be due to differences
in germination rates in vivo as well as a number of other possible factors. Since
the in vitro germination assay reveal that CamSA was not an inhibitor of
germination strain 630 spores with less than 100 μM of compound, it is not
surprising that CamSA was unable to prevent CDI against strain 630 spores. It is
possible that CamSA does not inhibit strain 630 spore germination even at higher
concentrations.
Compound 07C reduced and delayed CDI symptoms in strain 630challenged mice (Figure 3.4C). 07C-treated mice still developed CDI symptoms,
but only with a maximum mean symptoms severity score of 2.6, which reaches
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into the mild CDI range (Table 3.4). One mouse approached a score of a 4,
indicating mild CDI. While the positive control mice displayed maximum
symptoms at 48 hours post-infection, 07C-treated mice CDI peaked at 72 hours
post-challenge. Considering that mice were given the last dose of 50 mg/kg
07C at 48 hours post-infection, it is possible that the discontinuation of treatment
resulted in the delay of CDI. One study revealed that strain 630 spores shed over
a 96-hour timeframe.90 It is unknown when strain R20291 spores fully shed from
feces, though they may remain in the gut over the 48 hours (after treatment is
discontinued). Therefore, extending bile salt analog treatment may fully prevent
germination of strain R20291 spores in the gut until they are shed.
All surviving mice were kept for at least seven more days for observation.
None of the mice had disease relapse. All surviving mice appeared to fully
recover from initial CDI.

3.3.5 Analysis of CDI Symptoms in Mice Challenged with strain 9001966
C. difficile strain 9001966-challenged mice begin to have mild-tomoderate CDI starting at 24 hours post-challenge (Figure 3.5A). At 48 hours postchallenge, two mice reached scores of 6 (moderate CDI) (Table 3.5). Both at 24
and 48 hours post-challenge, mean symptoms severity was 4.6 (mild-tomoderate CDI). At 72 hours, maximum mean symptoms severity was reached
(score of 5.2) and all mice had moderate CDI. Interestingly, the mice remain sick
until 120 hours post-challenge, when they begin to recover. Although data past
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120 hours is not shown, the mice continued to be monitored and all fully
recovered from CDI by 144 hours post-challenge.
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Table 3.5. Mean CDI symptoms severity for mice challenged with strain 9001966 spores.

9001966 Group

24 h

48 h

72 h

96 h

120 h

Control

4.6

4.6

5.2

4.6

0.4

CamSA-treated

0.5

1.25

3.5

2.0

0.75

07C-treated

0.25

1.0

0.75

3.0

2.25

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI, orange = moderate CDI

Although CamSA and 07C did not fully protect CDI in strain 9001966challenged mice, both compounds reduced CDI symptoms significantly (Figure
3.5B-C). Average symptoms severity scores were 3.5 for CamSA-treated mice
and 3.0 for 07C treated mice, both representing mild CDI (Table 3.5). Curiously,
both onsets of maximum symptoms also appeared later than the control. This,
again, could be related to the cessation of treatment, allowing remaining
spores in the gut to germinate.
CamSA was unable to prevent strain 9001966 spore germination in vitro,
though it was able to reduce CDI symptoms in mice. CamSA may be active
against strain 9001966 spores in vitro at higher concentrations. 07C was able to
inhibit germination of strain 9001966 spores with an IC50 of 7.60 μM. Oddly,
although the IC50 of 07C against strain 630 is slightly higher at 8.19 μM, 07C fully
prevented CDI in strain 630-challenged mice. Therefore, there may not be a
direct correlation in in vitro IC50 values and in vivo CDI symptoms severity. This
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may be due to C. difficile inter-strain variability or other variables present in each
individual mouse’s gut.

3.3.6 Analysis of CDI Symptoms in Mice Challenged with strain 05-1223-046
In vivo, both CamSA and 07C were able to reduce CDI symptoms in mice
given C. difficile strain 05-1223-046 spores (Figure 3.6B-C). Mean CDI symptoms
severity scores at all time points indicate non-diseased mice. However,
untreated mice did not develop as intense symptoms as untreated mice given
other strains (Figure 3.6A). The difference between treated and untreated mice
was still statistically significant, though to different degrees depending on the
times point. Maximum mean symptoms severity in untreated mice occurs at 24
and 48 hours and is only a score of 3.0, which is at the lower end of mild CDI
(Table 3.6). This brings speculation about strain 05-1223-046’s resistance to
germination with the natural germinants taurocholate and glycine.
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Table 3.6. Mean CDI symptoms severity for mice challenged with strain 05-1223-046 spores.

05-1223-046 Group

24 h

48 h

72 h

96 h

120 h

Control

3.0

3.0

2.4

2.0

0

CamSA-treated

0

0.2

1.2

0.4

0

07C-treated

0.6

1.0

1.4

1.8

0.8

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI

3.3.7 Analysis of CDI Symptoms in Mice Challenged with strain CDC 38
Mice challenged with C. difficile strain CDC 38 spores displayed onset of
maximum mean symptoms severity score of 4.2 at 24 hours post-infection,
signifying mild-to-moderate CDI (Figure 3.7A, Table 3.7). The intensity of CDI
steady decreased over time until all mice eventually recovered around 120
hours post-infection.
CamSA was unable to prevent or significantly reduce CDI symptoms in
strain CDC 38-infected mice (Figure 3.7B). The highest achieved scored was by
one mouse at 24 hours with a score of 5 (moderate CDI). The remaining mice
reached mild-to-moderate CDI at 48 hours. At that time, the maximum mean
symptoms severity score of 3.8 (mild CDI) was attained (Table 3.7).
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Table 3.7. Mean CDI symptoms severity for mice challenged with strain CDC 38 spores.

CDC 38 Group

24 h

48 h

72 h

96 h

120 h

Control

4.2

3.4

2.8

2.0

0.4

CamSA-treated

0

3.2

3.8

1.6

1.0

07C-treated

0.4

3.4

3.2

1.8

1.6

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI

Of all the strains tested in the mouse CDI model, 07C appears to be the
least potent against strain CDC 38. 07C-treated mice still developed mild CDI
with a maximum mean symptoms severity of 3.4 (mild CDI) at 48 hours postchallenge (Figure 3.7C). However, this was a mild score reduction from the
untreated mice mean score of 4.2 (mild-to-moderate) at 24 hours postchallenge (Table 3.7). This decrease is statistically insignificant. Ironically, 07C
had quite a low IC50 of 4.62 μM against strain CDC 38. In vivo, mice may require
higher dosages of 07C for it to be an effective prophylactic against this strain.

3.3.8 Analysis of CDI Symptoms in Mice Challenged with strain DH1834
C. difficile strain DH1834-challenged mice had a steady progression to
maximum symptoms (Figure 3.8A). Starting at 24 hours, mice began to develop
CDI symptoms. However, maximum mean symptoms severity was occurred at 72
hours, with a score of 4.6, indicating mild-to-moderate CDI (Table 3.8). One
mouse reached a score of 7 and reached clinical endpoint. At 96 hours,
108

remaining mice recovered and remained asymptomatic for at least seven more
days.
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Table 3.8. Mean CDI symptoms severity for mice challenged with strain DH1834 spores.

DH1834 Group

24 h

48 h

72 h

96 h

120 h

Control

4.0

3.4

4.6

2.75

2.5

CamSA-treated

4.6

2.75

3.0

0.75

1.5

07C-treated

3.4

0.8

0.8

0.2

0.6

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI

CamSA did not prevent CDI in mice challenged with strain DH1834 spores
(Figure 3.8B). Mice developed maximum mean symptoms severity score of 4.6
(mild-to-moderate CDI) at 24 hours (Table 3.8). Symptoms severity continued to
drop from 48 hours on. 07C also did not reduce CDI symptoms to a significant
degree, however, it did significantly cut symptoms severity in the following days
(Figure 3.8B). Maximum mean symptoms severity in 07C-treated mice was 3.4,
which is a slight decrease from the positive CDI control (Table 3.8). As 07C also
has a low IC50 of 4.15 μM against strain DH1834 spores, other in vivo factors may
play a role in the germination of strain DH1834 spores.

3.3.9 Analysis of CDI Symptoms in Mice Challenged with strain 7004578
Like with strain 05-1223-046, the maximum mean symptoms severity for strain
7004578 was also in the mild CDI range (Figure 3.9A). In the in vitro germination
profile study, both of these strains had difficulty germinating in the presence of
the natural activators. However, the reason for the low mean score of 3.2 at 24
110

hours post-challenge was mainly due to two animals remaining asymptomatic
throughout the duration of the experiment (Table 3.9). Of the three remaining
mice, two mice reached clinical endpoint: one at 24 hours and the other at 48
hours. The third mouse kept a steady score of 4 (mild CDI) from 24 hours to 72
hours, until it began to recover at 96 hours. Although the two non-diseased mice
could not be considered as outliers, another graph was added to the figure
below to provide an alternative view of disease progression (Figure 3.9B).
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Table 3.9. Mean CDI symptoms severity for mice challenged with strain 7004578 spores.

7004578 Group

24 h

48 h

72 h

96 h

120 h

Control

3.2

2.75

1.33

0.67

0.33

CamSA-treated

2.75

3.25

2.0

1.5

1.75

07C-treated

0

0

0

0.4

0.2

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI

CamSA was not effective at preventing or reducing CDI symptoms of
mice given strain 7004578 spores. There is no statistically significant difference
between symptoms of CamSA-treated mice and untreated mice (Figure 3.9C).
Maximum mean symptoms severity for CamSA-treated mice occurred at 48
hours with a score of 3.25 (mild CDI) (Table 3.9). However, 07C was able to
prevent CDI altogether with strain 7004578-challenged mice remaining nondisease throughout duration of the experiment (Figure 3.9D).

3.3.10 Analysis of CDI Symptoms in Mice Challenged with strain 8085054
CDI symptoms of C. difficile strain 8085054-infected mice displayed a
similar progression of disease to mice infected with strain 630 and strain R20291
(Figure 3.10A). Positive CDI control mice that received strain 8085054 spores
presented with mild CDI (mean score of 3.4) at 48 hours post-infection (Table
3.10). At 72 hours and beyond, mice gradually recovered and did not relapse.
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Table 3.10. Mean CDI symptoms severity for mice challenged with strain 8085054 spores.

8085054 Group

24 h

48 h

72 h

96 h

120 h

Control

0.4

3.4

2.4

1.2

0.4

CamSA-treated

0

0

0.2

1.0

1.0

07C-treated

0

0.6

1.2

0

0.8

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI

Both CamSA and 07C prevented or reduced CDI symptoms for this strain
(Figure 3.10B-C). CamSA also appeared maximum symptoms in a couple mice
until 96 hours. Most mice were non-diseased throughout the experiment (Table
3.10). 07C-treated mice received scores of 0 to 2, marking them as nondiseased (Table 3.10). In vitro, 07C had the lowest IC50 value (1.28 μM) against
strain 8085054. In this case, the in vitro data reflects the in vivo results.

3.3.11 Comparison of CDI Symptoms Among All Tested C. difficile Strains
The eight tested C. difficile strains exhibited distinct CDI disease
progression and symptoms severity (Table 3.11). The range in onset of maximum
symptoms also vary among strains. Strains R20291 and 9001966 both presented
with the highest maximum mean symptoms severity with a score of 5.2,
indicating moderate CDI. Some of those mice also became moribund. Strain
R20291 is the hypervirulent strain of ribotype 027. Therefore, it is expected that
mice given this strain would display more severe CDI. Strains 630, CDC 38, and
DH1834 all showing mild-to-moderate CDI. However, the onset of maximum
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symptoms all vary between the three strains. Strain 05-1223-046, 7004578, and
8085054 only presented with averages of mild CDI, although some mice
became more symptomatic than others.

Table 3.11. Comparison of mean CDI symptoms for all positive control mice.

Strain

24 h

48 h

72 h

96 h

120 h

630

2.0

4.2

0.5

0.5

0

R20291

1.0

5.2

2.0

1.25

0.75

9001966

4.6

4.6

5.2

4.6

0.4

05-1223-046

3.0

3.0

2.4

2.0

0

CDC 38

4.2

3.4

2.8

2.0

0.4

DH1834

4.0

3.4

4.6

2.75

2.5

7004578

3.2

2.75

1.33

0.67

0.33

8005054

0.4

3.4

2.4

1.2

0.4

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI, orange = moderate CDI

Mice also responded differently to bile salt analog treatment depending
on the C. difficile strain used for challenge (Table 3.11 and 3.12). CamSA was not
expected to be able to prevent CDI any C. difficile strains other than strain 630
since the in vitro data suggested that it was only a potent inhibitor against that
strain. However, CamSA showed some promising results with some strains in the
mouse CDI model. CamSA prevented CDI in strain 630, as predicted, but also in
strains 05-1223-046 and 8085054. Symptoms reduction was seen in strain 9001966
116

in CamSA-treated mice. Thus, the concentration of CamSA may need to be
increased much more against these strains in vitro to possibly determine
inhibitory concentrations against germination. In contrast, CamSA was not
effective against strains R20291, CDC 38, DH1834, and 7004578.

Table 3.12. Comparison of mean CDI symptoms for all CamSA-treated mice.

Strain

24 h

48 h

72 h

96 h

120 h

630

0

0.2

0.2

0

0.2

R20291

1.0

4.2

4.75

1.25

0

9001966

0.5

1.25

3.5

2.0

0.75

05-1223-046

0

0.2

1.2

0.4

0

CDC 38

0

3.2

3.8

1.6

1.0

DH1834

4.6

2.75

3.0

0.75

1.5

7004578

2.75

3.25

2.0

1.5

1.75

8005054

0

0

0.2

1.0

1.0

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI, orange = moderate CDI

07C significantly prevented, reduced, or reduced and delayed CDI
symptoms in mice challenged with almost all strains tested. The only strain that
showed the most insignificant symptom reduction against was strain CDC 38. In
strains 630, 05-1223-046, 7004578, and 8085054, mice were considered nondiseased when treated with 07C. Symptom onset was delayed with the
hypervirulent strain R20291. However, CDI was greatly reduced in mice
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challenged with strain R20291. CDI symptoms were reduced and delayed with
strain 9001966-infected mice. Finally, with strain DH1834, maximum symptoms
were only mildly reduced, but mice did exhibit delayed protection at the
subsequent time points.

Table 3.13. Comparison of mean CDI symptoms for all 07C-treated mice.

Strain

24 h

48 h

72 h

96 h

120 h

630

0.4

0

0

0

0

R20291

0

2.0

2.6

0.2

0.6

9001966

0.25

1.0

0.75

3.0

2.25

05-1223-046

0.6

1.0

1.4

1.8

0.8

CDC 38

0.4

3.4

3.2

1.8

1.6

DH1834

3.4

0.8

0.8

0.2

0.6

7004578

0

0

0

0.4

0.2

8085054

0

0.6

1.2

0

0.8

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI, orange = moderate CDI

3.4 Conclusions
The mouse CDI model has demonstrated the powerful potential of bile salt
analogs in the prophylactic treatment of CDI in mice. By using the in vitro
germination profile data, we made predictions about the outcomes of the in
vivo mouse CDI model. However, although some in vitro data reflected in vivo
findings, others did not show a direct correlation. This may be due to different
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germination rates of spores of certain C. difficile strains in vivo. This could be
caused by, but not limited to, natural bile acids found within the gut, the mouse
gut microbiota, diet, and cage dominance. These variables as well as others will
need to be explored in further research. In the meantime, the results of this study
illustrate the general patterns of disease and inhibitory abilities of the bile salt
analogs. CamSA can reduce or prevent CDI symptoms in mice for a few tested
strains, while 07C is able to reduce, prevent, or reduce and delay CDI symptoms
in mice with all but one strain tested. By modifying treatment while discovering
new bile salt analogs, we may be able to find a potent prophylactic treatment
option to be treated on CDI-inflicted organisms.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS
4.1 Conclusions
CDI is an antibiotic-associated disease that is localized to the GI tract.
After C. difficile spores become ingested through contact with various mediums
such as table surfaces, food, animals, and unwashed hands, they undergo a
transformative process while in the anaerobic intestines called germination.
Bacterial cells that are capable of producing damage-inducing toxins arise from
this germination process. CDI poses a serious threat to predisposed individuals
who have weakened immune systems or who have recently taken antibiotics
that deplete their natural protective bacterial barrier in the gut. With the
emergence of new and hypervirulent strains of C. difficile, well individuals can
also be vulnerable to CDI.
C. difficile spores germinate when in the presence of promoters called
germinants. These germinants, specifically taurocholate, are bile acids that are
naturally produced in the liver. Smaller amino acid co-germinants like glycine
aid the germination process by increasing cooperative binding affinity of other
co-germinants to the spore. Conversely, a few naturally occurring bile acids
such as chenodeoxycholate can act as germination inhibitors. In individuals with
gut microbiome imbalances, the germinant bile acids cannot be regulated
efficiently by the indigenous intestinal microorganisms and inhibitor bile acids
are not strong enough to protect from CDI in an overabundance of germinants.
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Synthetic bile salt analogs have been proposed to act as more potent
germination inhibitors than the natural inhibitor. One analog called CamSA was
effective at preventing spore germination of strain 630 and CDI symptoms
against a few other C. difficile strains in the CDI mouse model, while another
analog called 07C was a powerful anti-germinant and CDI symptom
reducer/preventer in multiple C. difficile strains. These bile salt analogs act as
prophylactics against CDI and open the gateway to navigating the C. difficile
germination pathway.
Germination assays were used to test bile salt analogs’ in vitro activity in
preventing spore germination. CamSA was only able to prevent spore
germination of strain 630 at less than 100 μM final concentration, while 07C
inhibited germination of strains 630, R20291, 9001966, CDC 38, and DH1834
spores. Inhibitory activity could not be determined for strains 05-1223-046 and
7004578 as they were both unable to germinate in the presence of the natural
activators taurocholate and glycine. No major germination profile similarities
were found in different strains from the same ribotype group. The calculated IC50
values from the germination assays provided a general outline of expectations
for the in vivo study and were used for comparison purposes.
The bile salt analogs were tested as prophylactic agents against the
various C. difficile strain spores in vivo in the CDI mouse model. Mice were
challenged with an inoculum containing 108 C. difficile spores via orogastric
administration. Mice symptoms severity varied among each tested C. difficile
121

strain. Maximum CDI scores in untreated mice ranged from 4-8 on the day of
maximal symptoms. Similarly, duration of disease symptoms also differed
between strains. Interestingly, CamSA was not only able to protect mice from
CDI when challenged with strain 630 spores, but it also prevented CDI symptoms
in mice challenged with strains 05-1223-046 and 8085054, and reduced CDI
symptoms in mice challenged with strains 9001966 and delayed symptoms in
one mouse given strain 8085054. Overall, 07C was effective in preventing,
reducing, or both reducing and delaying CDI in almost all tested strains.
Compound 07C protected mice challenged with 630, 05-1223-046, 7004578,
and 8085054. Mice challenged with strain R20291 experienced a one day delay
in symptoms onset, and the mean symptoms severity was significantly lower in
the 07C-treated mice compared to the control. Delay of maximum symptom
onset was also noted in mice that received strain 9001966 spores. DH1834infected mice treated with 07C experienced a slight reduction in CDI symptoms
and quick recovering soon thereafter. Of all the tested strains 07C seemed to be
least effective against strain CDC 38 with only an insignificant reduction and
delay in CDI symptoms.
The in vitro IC50 values for each strain did not correlate with the degree of
protection from CDI in vivo. However, the more potent compound, 07C, was
generally a better prophylactic against multiple C. diffiicle strains than CamSA.
The differences between in vitro and in vivo activities could be due to the
influences that may only be present in living systems. A considerable amount of
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heterogeneity in symptoms severity was found among mice of the same cage
and treatment regimen. Although variables such as dosages, temperature, and
light cycles were well controlled, other variables include ad libitum drinking of
the antibiotic cocktail, mouse dominance, and epigenetic factors are more
difficult to control.
4.2 Research Questions
The findings from both the in vitro and in vivo studies raise a few questions
about variables that may confound results. To recap on peculiar discoveries
from the in vitro study, two C. difficile strains, 05-1223-046 and 7004578, were
unable to germinate in the presence of the germinants taurocholate and
glycine. As previously mentioned in chapter 2, the appropriate amino acid cogerminant required for germination may not be the expected glycine.
Alternatively, the co-germinant may be a molecule other than an amino acid.
Once a suitable co-germinant is found, another question to answer is whether
CamSA and 07C act as active inhibitors against those strains.
For the in vivo study, many possibilities may be responsible for the
heterogeneity found within each group of mice. A recent article discussed the
variability found between seemingly identical mice and associated it with
minute and difficult-to-control factors.203 One proposed variable was sex. All
mice used in the study were weaned female C57BL/6 mice. By the time mice
were mature enough to be used in the study, they were of age to enter
menarche (start of the estrous cycle). As most CDI mice studies are performed
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using female mice, the variation between sexes was not yet considered. No
current or previously published studies have explored the differences between
male and female mice CDI thoroughly. One hallmark CDI mice study that
happened to use both male and female mice showed similar symptoms severity
between the two sexes.200
Estrogen has been suggested to play a role in mediating gut
inflammatory response and modifying intestinal permeability.204,205 Studies have
found that post-menopausal women are at higher risk for intestinal diseases such
as Crohn’s disease and Irritable Bowel Syndrome (IBS).206 Increased inflammatory
bowel diseases (IBD) have also been associated with pregnancy and use of oral
contraceptives.206,207 Furthermore, previous work from the Abel-Santos
Laboratory showed that progesterone analogs affect in vitro germination of C.
difficile spores.208 These results are intriguing since steroidal hormones share the
same cholic backbone with bile salts.209 Therefore, regulation of estrogen via the
estrous cycle may play a role in other intestinal diseases like CDI. Although
estrogen’s role in Crohn’s and IBS have been well researched, estrous cycle
effects on CDI have yet to be examined. Higher susceptibility to intestinal
inflammation post-menopause may contribute to the increased CDI risk in
elderly women. Conversely, changes in gut microbiota can also effect estrogen
excretion and reuptake.205 Imbalances in intestinal microflora can cause an
increase in β-glucuronidase, which can uncouple the normally excreted
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estrogen-glucuronic acid complex, causing estrogen to be more readily
reabsorbed by the gut, thus resulting in increased estrogen load.210
We conducted a preliminary experiment to investigate differences
between male and female CDI symptoms severity. The primary purpose of this
experiment was to see if male mice experience more homogenous symptoms
than female mice. Experimental setup was performed in the same manner as
with other mouse CDI model experiments outlined in chapter 3. All cages were
run in tandem. All mice were of the same age and were post-pubescent.
Although heterogeneity still existed, disease symptoms are statistically less
severe in males than in female in the control groups (Figure 4.1, Table 14.1). Also,
males seemed to have a more heterogenous spread than females (Figure 4.2).
Of the five males in the control cage, two remained asymptomatic, while the
other three had mild to moderate CDI. Interestingly, bile salt analogs failed to
protect male mice from CDI. Although there have been several studies done on
estrogen effects on several types of GI afflictions, testosterone effects have not
been well characterized. It may still be advantageous to continue using female
mice model; since male mice get slightly less sick from CDI, having female mice
that are more susceptible to CDI may be important for observing minor changes
in symptoms severity between regimens.
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Table 4.1. Comparison of mean CDI symptoms for all 9001966-challenged mice groups.

9001966 Group

24 h

48 h

72 h

96 h

120 h

Females Control

0

3.0

3.6

0

0

Males Control

0

2.4

1.8

1.0

0

Females with CamSA

0

0.4

0

0

0

Males with CamSA

0

2.2

1.6

0.6

0.2

Females with 07C

0

2.8

1.4

0.6

0

Males with 07C

0

2.8

1.4

0.2

0.2

KEY: light green = non-disease, green = non-diseased-to-mild CDI, yellow = mild CDI, yelloworange = mild-to-moderate CDI, orange = moderate CDI

On a similar note, diet has also been shown to affect the diverse gut
enterotypes. Thus, this may also have an effect of the prognosis of CDI. Longterm studies have shown that high levels of genus Bacteroides bacteria in the
gut are linked to high protein and animal fat intake.211 Similarly, increase
carbohydrate consumption is associated with genus Prevotella bacterial
prevalence.211 Imbalance of these gut microbe could influence the progression
of CDI.
Another uncertainty is whether symptom heterogeneity is caused by
discrepancies in sporulation or in bile salt activation. As mentioned in section
1.2.2, differences in sporulation rates among various C. difficile strains may
account for variation of symptoms onset and severity among mice. In vivo
conditions may influence when spores germinate in the gut. One study using C.
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difficile strain 630 revealed that spore shedding occurs over a 96-hour period
from the time of infection.90 Therefore, strain 630 sporulation may occur up to
that point. Moreover, recovered spores were undistinguishable from spore of the
original inoculum, so it is possible that newer spores could be formed in the GI
tract.90 These discoveries were only made for strain 630; other strains may
behave differently in vivo.
At the bile salt level, cleavage of side chains in vivo by native gut
microorganisms may also be probable. As a site of bile salt modification, the
intestinal tract may also modify synthetic bile salt analog side chains. Therefore,
finding a stable inhibitor is necessary. One study done by past members of the
Abel-Santos Laboratory showed that CamSA was stable toward bile salt
hydrolases.90
4.3 Future Directions
There is a plethora of paths that can be explored to follow-up this thesis
study. As this study is completed, other bile salt analogs are being tested as
potential potent germination inhibitors. At this time, no other screened bile salt
analog has shown in vitro inhibitory activity as powerful as compound 07C.
To address the issue of other possible C. difficile spore germinants, amino
acid analogs will be tested with strains 05-1223-046 and 7004578 spores via
germination assays. The most suitable germinant will be used to identify whether
bile salt analogs CamSA and 07C demonstrate anti-germinants behavior.
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Another matter to investigate is whether CamSA is an active inhibitor at
higher concentrations. Although CamSA was not shown to be an active antigerminant against five of the six testable C. difficile strains at low micromolar
concentrations in vitro, CamSA was able to reduce CDI symptoms in mice given
certain C. difficile strains. Also, IC50 value was not found to have direct
correlation to reduction of CDI symptoms possibly due to a number of in vivo
factors to take into account. However, germination inhibition with CamSA in
vitro may explain why it still exhibits prophylactic activity in mice that receive C.
difficile strains other than strain 630.
Now that some results have been established in the prophylactic mice
CDI model again various C. difficile isolates, we can adjust treatment regimens
to cater to each individual strain. For some strains, upping the concentration of
bile salt analog compound may necessary for protection from CDI. As no
toxicity was observed at 300 mg/kg compound and only 50 mg/kg was given to
C. difficile infected mice, increasing the concentration of bile salt analogs
below 300 mg/kg should be non-toxic. Following that study, we can modify bile
salt analog compound regimens to test on the extremely susceptible hamster
model. As mentioned in chapter 3, CamSA protected hamsters from CDI when
synergistically paired with vancomycin treatment. However, one animal did
reach demise. By tailoring the treatment plans per strain, the potent inhibitor
07C may have effective prophylactic effects in the hamster model.
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Further investigations into sex effects on CDI may be studied in more
detail. If the estrous cycle may be a culprit in the heterogeneity of mice CDI
symptoms, a vaginal epithelial swab can be used to determine the mice’s stage
in the estrous cycle. One caveat to using this method is that it would be difficult
to deliberately sync all mice in one cage to the same stage in the cycle.
However, the stages could be used to backtrack and find possible correlations
between them and CDI symptoms severity.
Issues concerning diet effects on gut microbiota can also be examined
using the mice model. Changes in enterotype composition can be tracked as
mice diet changes. Mice will be given different feeds containing an abundance
of one or more types of macromolecules. Moreover, CDI susceptibility of mice
on the special diets will be observed. Mice will then be treated with bile salt
analog prophylactics while on the specific diets.
To address concern of bile salt analog absorption by intestinal epithelium
or modification in the gut, an in vitro bind assay study will be used to test CamSA
and 07C’s binding to the intestinal chyme. This will give us an understanding of
how the absorptivity of these compounds by the intestinal epithelium. Moreover,
the bile salt analogs’ effect on the gut microbiota can also be studied further.
Because onset of CDI symptoms occurred rapidly within 48 hours for the
published study involving strain 630, bacterial loads following that timeframe
could not be determined as the mice reached moribund.90 By using a nontoxigenic C. difficile strain, shedding spores from feces will be easier to recover
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since mice will be asymptomatic. This also greatly minimizing possible suffering
for the animal. Using a non-toxigenic strain also brings up the question of
whether these non-toxigenic spores will still germinate in the gut like spores of
other strains do if untreated.
CDI is a quick spreading quandary as new strains of C. difficile are still
being discovered. Because of the variable responses of the strains to various
environments and factors, finding a “one-size-fits-all” solution may not be
possible for CDI. On top of that, there is also the conundrum that CDI is an
antibiotic-associated disease treated by antibiotics. Therefore, the exploration
into prophylactic treatment is indispensable. If these tested bile salt analogs can
protect animals from CDI, they may be used to control the prognosis of CDI as
molecular probes. This would lead CDI research one step closer to uncovering
the binding action of these bile salt germinants and inhibitors to the spore. By
focusing on the preventative capability of bile salt analogs like CamSA and 07C,
we may be able to flush away this poopy problem in the near future.
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APPENDIX
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Figure S1. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain 630 spores. These concentrations were used to construct the dose-dependent
curve to determine the IC50 of 07C against strain 630. Spores were resuspended in
germination buffer and treated with neat DMSO (●) or treated with a fixed concentration of
taurocholate (6 mM) and glycine (12 mM) added to final concentrations of 0 μM (●), 3.125
μM (●), 6.25 μM (●), 9.375 μM (●), 12.5 μM (●), 15.625 μM (●), 25 μM (●), 31.25 μM (●), 37.5 μM
(●), 40.625 μM (●), and 50 μM (●) 07C. In actuality, data was collected every minute for 120
minutes. For clarity, data at five minute intervals are shown and error bars signifying standard
deviation were eliminated. The data points indicate the means from three independent
measures (n = 3).
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Figure S2. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain R20291 spores. These concentrations were used to construct the dosedependent curve to determine the IC50 of 07C against strain R20291. Spores were
resuspended in germination buffer and treated with neat DMSO (●) or treated with a fixed
concentration of taurocholate (6 mM) and glycine (12 mM) added to final concentrations of
0 μM (●), 0.048828 μM (●), 0.146484 μM (●), 0.195313 μM (●), 0.390625 μM (●), 0.585938 μM (●),
0.78125 μM (●), 1.171875 μM (●), 1.5625 μM (●), 2.34375 μM (●), 6.25 μM (●), 9.375 μM (●),
15.625 μM (●), 25 μM (●), and 28.125 μM (●) 07C. In actuality, data was collected every
minute for 120 minutes. For clarity, data at five minute intervals are shown and error bars
signifying standard deviation were eliminated. The data points indicate the means from three
independent measures (n = 3).
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Figure S3. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain 9001966 spores. These concentrations were used to construct the dosedependent curve to determine the IC50 of 07C against strain 9001966. Spores were
resuspended in germination buffer and treated with neat DMSO (●) or treated with a fixed
concentration of taurocholate (6 mM) and glycine (12 mM) added to final concentrations of
0 μM (●), 1.5625 μM (●), 2.34375 μM (●), 3.125 μM (●), 6.25 μM (●), 9.375 μM (●), 15.625 μM (●),
18.75 μM (●), 25 μM (●), 31.25 μM (●), 37.5 μM (●), and 40.875 μM (●) 07C. In actuality, data
was collected every minute for 120 minutes. For clarity, data at five minute intervals are
shown and error bars signifying standard deviation were eliminated. The data points indicate
the means from three independent measures (n = 3).
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Figure S4. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain CDC 38 spores. These concentrations were used to construct the dosedependent curve to determine the IC50 of 07C against strain CDC 38. Spores were
resuspended in germination buffer and treated with neat DMSO (●) or treated with a fixed
concentration of taurocholate (6 mM) and glycine (12 mM) added to final concentrations of
0 μM (●), 0.1953125 μM (●), 0.390625 μM (●), 0.78125 μM (●), 1.5625 μM (●), 2.34375 μM (●),
3.90625 μM (●), 4.6875 μM (●), 6.25 μM (●), 9.375 μM (●), 12.5 μM (●), 15.625 μM (●), 25 μM (●),
and 37.5 μM (●) 07C. In actuality, data was collected every minute for 120 minutes. For
clarity, data at five minute intervals are shown and error bars signifying standard deviation
were eliminated. The data points indicate the means from three independent measures (n =
3).
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Figure S5. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain DH1834 spores. These concentrations were used to construct the dosedependent curve to determine the IC50 of 07C against strain DH1834. Spores were
resuspended in germination buffer and treated with neat DMSO (●) or treated with a fixed
concentration of taurocholate (6 mM) and glycine (12 mM) added to final concentrations of
0 μM (●), 0.78125 μM (●), 1.171875 μM (●), 1.5625 μM (●), 3.90625 μM (●), 4.6875 μM (●), 6.25
μM (●), 12.5 μM (●), 15.625 μM (●), and 18.75 μM (●) 07C. In actuality, data was collected
every minute for 120 minutes. For clarity, data at five minute intervals are shown and error
bars signifying standard deviation were eliminated. The data points indicate the means from
three independent measures (n = 3).
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Figure S6. Germination kinetic graph containing various concentrations of 07C against C.
difficile strain 8085054 spores. These concentrations were used to construct the dosedependent curve to determine the IC50 of 07C against strain 8085054. Spores were
resuspended in germination buffer and treated with neat DMSO (●) or treated with a fixed
concentration of taurocholate (6 mM) and glycine (12 mM) added to final concentrations of
0 μM (●), 0.01220703125 μM (●), 0.0244140625 μM (●), 0.048828125 μM (●), 0.09765625 μM (●),
0.146484375 μM (●), 1.171875 μM (●), 1.5625 μM (●), 9.375 μM (●), 12.5 μM (●), 15.625 μM (●),
25 μM (●), 28.125 μM (●), 37.5 μM (●), 43.75 μM (●), and 50 μM (●) 07C. In actuality, data was
collected every minute for 120 minutes. For clarity, data at five minute intervals are shown
and error bars signifying standard deviation were eliminated. The data points indicate the
means from three independent measures (n = 3).
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